

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 896 058 A1

(12)

EUROPEAN PATENT APPLICATION

published in accordance with Art. 158(3) EPC

(43) Date of publication:

10.02.1999 Bulletin 1999/06

(21) Application number: 96939335.4

(22) Date of filing: 02.12.1996

(51) Int. Cl.⁶: **C12N 15/12**, C07K 14/47,
C12P 21/02, C12N 1/21,
C12N 5/10, C12N 7/01,
C07K 16/18, C12P 21/08,
A61K 38/17, A01K 67/027
// (C12N1/21, C12R1:19),
(C12P21/02, C12R1:19),
(C12N5/10, C12R1:91)

(86) International application number:
PCT/JP96/03517

(87) International publication number:
WO 97/20928 (12.06.1997 Gazette 1997/25)

(84) Designated Contracting States:

AT BE CH DE DK ES FI FR GB GR IE IT LI NL PT
SE

(30) Priority: 06.12.1995 JP 345187/95

31.10.1996 JP 307205/96

(71) Applicant:

SUMITOMO PHARMACEUTICALS COMPANY,
LIMITED
Osaka-shi, Osaka-fu 541 (JP)

(72) Inventors:

- KIMURA, Toru
Kusatsu-shi, Shiga 525 (JP)
- KIKUCHI, Kaoru
Takaraduka-shi, Hyogo 665 (JP)

(74) Representative:

VOSSIUS & PARTNER
Postfach 86 07 67
81634 München (DE)

(54) **NOVEL SEMAPHORIN Z AND GENE ENCODING THE SAME**

(57) Novel semaphorin Z; a gene thereof; a partial peptide of the semaphorin Z; an antibody; a DNA or an RNA complementary to the semaphorin Z gene; a method for screening a semaphorin Z inhibitor by using the semaphorin Z; the semaphorin Z inhibitor obtained by the screening; and a CNS neuron regeneration promoter comprising the inhibitor.

EP 0 896 058 A1

Description

TECHNICAL FIELD

5 [0001] The present invention relates to Semaphorin Z, a novel Semaphorin belonging to the Semaphorin family, and use of Semaphorin Z for pharmaceutical agents or laboratory reagents. More particularly, it relates to Semaphorin Z inhibiting neurite outgrowth, and a gene encoding the same, as well as other Semaphorins hybridizing to said Semaphorin Z gene. Furthermore, the present invention relates to modified proteins or partial peptides of Semaphorin Z, antibodies against Semaphorin Z, DNAs or RNAs complementary to said Semaphorin Z gene, and their use for
10 pharmaceutical or diagnostic agents or laboratory reagents.

BACKGROUND ART

[0002] It is widely known that a central nervous system (CNS)-neuron in higher organisms such as human is not capable of regeneration once injured. Therefore, one who has received an injury on his (her) spinal cord due to, for example, a traffic accident is compelled to spend the rest of his (her) life in a hemiplegic state. On the contrary, it is known that a peripheral nervous system (PNS)-neuron retains a vigorous regeneration ability even in those higher organisms, and therefore, neurons in a limb, when disconnected, can gradually regenerate with a concomitant recovery of their function.

[0003] In early nineteen-eighties, a group of Aguayo *et al.* found that when PNS-neuron is experimentally grafted into an injured CNS-neuron in a higher organism, axon growth of CNS-neuron is induced. This observation demonstrates that CNS-neuron in higher organisms which had been generally considered not to have a regeneration ability can regenerate if a suitable environment is provided (*Nature*, 284, 264-265 (1980), *Science*, 214, 931-933 (1981)). That report suggests a possibility that in CNS of higher organisms, there may exist a factor, namable "CNS-neuron regeneration inhibitor", which inhibits the regeneration of CNS-neuron, and that a release from such inhibition may allow the
25 regeneration of CNS-neurons. This suggestion paved the way for a CNS-neuron regeneration therapy.

[0004] In 1988, a group of Schwab *et al.* demonstrated that there existed such CNS-neuron regeneration inhibitor among proteins derived from CNS myelin. They also succeeded in purifying, though partially, a protein having said CNS-neuron regeneration inhibition activity, and named this protein fraction NI35/250 (*Annu. Rev. Neurosci.*, 16, 565-595 (1993)), although no one has succeeded in its isolation, identification and gene cloning yet. In addition, they immunized animals with the partial purified NI35/250, and succeeded in obtaining an antibody (IN-1) having a neutralizing activity. This antibody is capable of recognizing a band for NI35/250 in Western blotting, and capable of staining, in an immunostaining, the region where NI35/250 is supposed to be distributed. Furthermore, they demonstrated that administration of this antibody to an animal experimentally received an injury on its spinal cord has promoted regeneration of axons in spinal cord, though partially, within 2-3 weeks, and restored its function within 2-3 months (*Nature*, 343, 269-272 (1990), *Nature*, 378, 498-501 (1995)). These findings are of great value, because they experimentally demonstrated that there existed a CNS-neuron regeneration inhibitor as suggested by Aguayo *et al.* (*supra*) and that CNS-neuron can be regenerated by inhibiting the activity of said inhibitor. The above noted antibody is, however, directed not to human but to rat NI35/250, and exhibits a low stability and specificity. In addition, although regeneration of CNS-neuron was observed as described above by administering said antibody, its effect was so partial and incomplete that not
40 all of the motor functions could be restored. It is, therefore, believed essential in solving these problems to identify the gene coding for NI35/250 or corresponding CNS-neuron regeneration inhibitor, and, based on knowledges of molecular biology, neuroscience and the like, develop an inhibitor effectively inhibiting the CNS-neuron regeneration inhibition activity, or develop a method for inhibiting the expression of the gene for said regeneration inhibitor.

[0005] Apart from the above, the nervous system, whether it is central or peripheral, requires formation of a complicated neural network among neurons or between neurons and peripheral receivers or effectors during development, that is, in the stage of embryo or fetus, in order to precisely carry out its principal functions, *i.e.*, to transfer and process the information. To establish the neural network, an ingenious mechanism is necessary, which precisely guides a growing neurite to the target site locating remote therefrom.

[0006] It has been hitherto believed that a factor which positively control the neurite outgrowth such as neurite growth promoter and neurite growth attractant may play a major role in the formation of the neural network. However, it is now being demonstrated by recent studies on the mechanism of the network formation that the opposite factor, that is, a negative factor having an outgrowth inhibition activity is important for an accurate guidance (*Cell*, 78, 353-356 (1994)).

[0007] A representative factor having such an outgrowth inhibition activity is a protein called "Semaphorin". Semaphorin firstly discovered is Fasciclin IV found in grasshopper. Collapsin (latterly named Collapsin I) was subsequently discovered in chick (*Cell*, 75, 217-227 (1993); *Neuron*, 9, 831-845 (1992)). To date, more than 10 genes belonging to the Semaphorin family have been reported in a wide range of species covering insects such as drosophila and beetle, human, and viruses (*Cell*, 81, 471-474 (1995)). These Semaphorins characteristically contains in their amino acid sequences a certain structure called semaphorin domain consisting of about 500 amino acids (*Neuron*, 14, 941-948

(1995); *Cell*, 75, 1389-1399 (1993)). However, the homologies of the primary amino acid sequences in Semaphorin domains among these Semaphorin genes are 80-20%, and not necessarily high.

[0008] Of these Semaphorins, functions have been verified for only a few, including, for example, Fasciclin IV of grasshopper, Semaphorins I and II of drosophila, Collapsin of chick, and Semaphorin III which corresponds to Collapsin in mammals. All of these Semaphorins are known to inhibit neurite outgrowth and synapsis formation. In particular, Semaphorin III has been reported to have an activity collapsing in a short time the growth cone of cultured neuron (growth-cone collapse activity) *in vitro* (*Neuron*, 14, 941-948 (1995); *Neuron*, 14, 949-959 (1995); *Cell*, 81, 631-639 (1995); *Cell*, 75, 1389-1399 (1993); *Cell*, 75, 217-227 (1993); *Neuron*, 9, 831-845 (1992)).

[0009] Although it is now being demonstrated, as described above, that Semaphorin has a growth-cone collapse activity and a neurite outgrowth inhibition activity during development, and plays a role in giving an accurate guidance to neuron, it is not evident at present whether or not Semaphorin exerts some function not only during development but also in the adult, and less evident whether or not Semaphorin plays a role as a CNS-neuron regeneration inhibitor. Of course, since Semaphorin has been shown to be a negative guidance factor inhibiting neurite outgrowth, it would not be unreasonable to consider said Semaphorin as a candidate for a CNS-neuron regeneration inhibitor (*Nature*, 378, 439-440 (1995)). However, it has been shown by *in vitro* experiments that Semaphorin III (Sema III), only one Semaphorin of higher organisms of which function has been analyzed, exerts its neurite-outgrowth inhibition activity on a sensory neuron and sympathetic neuron both of which are peripheral, but not on a retinal neuron which is central (*Cell*, 75, 217-227 (1993)). In addition, Northern analysis on the distribution of Sema III expression in the adult conducted by the present inventors has revealed that it is expressed mainly in peripheral tissues (see Reference example 2 below). It is therefore hardly believed that Sema III having such features has a function as a "CNS-neuron regeneration inhibitor".

PROBLEM TO BE SOLVED BY THE INVENTION

[0010] The present invention aims to provide Semaphorin Z, a novel Semaphorin inhibiting neurite outgrowth, and a gene therefor, and to provide a pharmaceutical or diagnostic agent for neural diseases, in particular an agent for regeneration of CNS-neuron, as well as a laboratory reagent. Based on the discovery of Semaphorin Z, the present invention also provides, for example, another Semaphorin gene hybridizing to said Semaphorin Z gene, a modified Semaphorin Z protein or a partial peptide of Semaphorin Z, an antibody against Semaphorin Z, DNA or RNA complementary to said Semaphorin Z gene, a screening method for Semaphorin Z inhibitor using Semaphorin Z, a Semaphorin Z inhibitor obtained by said screening method, a pharmaceutical composition comprising Semaphorin Z or an inhibitor thereof, a transgenic animal involving Semaphorin Z. Furthermore, the present invention provides a laboratory reagent for this technical field on the basis of the discovery of Semaphorin Z.

MEANS FOR SOLVING THE PROBLEM

[0011] If regeneration of CNS-neuron in the adult is always kept inhibited as described in the "Prior Art" section, it is believed that identification of a factor which inhibits regeneration of CNS-neuron is the most important subject to be solved for establishing a therapy for regeneration of CNS-neuron, and that any therapy for regeneration of CNS-neuron can not be established without identifying such factor.

[0012] The present inventors have paid their attention to the similarity between the *in vitro* activities of the above-described NI35/250 and Semaphorin, a negative guidance factor. Specifically, the present inventors have paid their attention to the fact that NI35/250 has a growth-cone collapse activity and a neurite-growth inhibition activity *in vitro* (*J. Neurosci.*, 8, 2381-2393 (1988); *Science*, 259, 80 (1993)), while known Semaphorins similarly possess a neurite-growth inhibition activity, and particularly Semaphorin III has also a growth-cone collapse activity. This suggested to the inventors the possibility that unknown Semaphorins which have not yet been identified may include the one having a function as a CNS-neuron regeneration inhibitor. Specifically, the present inventors' idea was that, although Semaphorin, which is characterized in that 1) it is highly expressed in CNS of adult and 2) it is poorly expressed in fetus or peripheral tissues in adult where the neurite outgrowth is not inhibited, has not been identified yet, if one can identify a new unknown Semaphorin having such characteristics, the Semaphorin might function as a CNS-neuron regeneration inhibitor.

[0013] Thus, a DNA sequence encoding amino acids relatively well conserved among previously reported Semaphorin genes was firstly determined using EST (Expressed Sequence Tags) database, and as a consequence, a DNA fragment T08532 was identified, which encodes, as a partial sequence, a sequence (Gln-Asp-Pro-Tyr-Cys-Gly-Trp-Ala) similar to that consisting of 8 amino acids highly conserved among Semaphorins (Gln (or Arg)-Asp-Pro-Tyr (or His)-Cys-Ala (or Gly)-Trp-Asp).

[0014] This T08532 sequence contained undetermined bases, and its open reading frame could not be determined. Furthermore, T08532 almost never contained any sequence which is common to Semaphorins, with the exception of the above amino acid sequence. Therefore, it could not be concluded at that stage that T08532 is part of the gene

encoding "Semaphorin". Furthermore, distribution of T08532 in fetus and adult tissues was absolutely unclear, and it was utterly impossible to expect that T08532 may be a part of the gene encoding a Semaphorin having a function as a "CNS-neuron regeneration inhibitor".

[0015] Thus, a DNA primer was firstly synthesized on the basis of the sequence information of T08532, and used in PCR reaction together with cDNAs prepared from a human hippocampal cDNA library as a template to clone a region corresponding to T08532 and determine the base sequence (SEQ ID NO: 7). Using the fragment thus cloned, rat and human cDNA libraries were then screened. As a result, the rat and human genes cloned in this procedures proved to be a novel Semaphorin gene having a sequence characteristic to Semaphorins. We named this novel Semaphorin "Semaphorin Z".

[0016] Subsequent analysis revealed that Semaphorin Z of the present invention is highly expressed in CNS in the adult, but scarcely expressed in other tissues except for spleen, and that its expression in embryos was considerably lower than that in the adult, demonstrating an expression distribution which is considered reasonable for "CNS-neuron regeneration inhibitor".

[0017] In addition, the present inventors have found that Semaphorin Z of the present invention has an inhibitory effect on neurite outgrowth. Furthermore, it has been found that a gene having a sequence complementary to Semaphorin Z gene inhibits the expression of Semaphorin Z.

[0018] Semaphorin Z of the present invention appears to be a CNS-neuron regeneration inhibitor in the adult, since it is highly expressed in CNS and inhibits neurite outgrowth as described above. The use of Semaphorin Z permits carrying out a screening to obtain Semaphorin Z inhibitor, and the inhibitor found by such screening system will be able to promote regeneration of CNS-neuron. Furthermore, since a gene having a sequence complementary to Semaphorin Z gene has inhibited the expression of Semaphorin Z as described above, such complementary gene may be used in a therapy for regeneration of CNS-neuron.

[0019] In addition, in view of the fact that Semaphorin Z of the present invention inhibits neurite outgrowth as described above, it may be used as a therapeutic or diagnostic agent for pains or immune diseases such as atopic dermatitis, by administering to peripheral tissues, which results in the inhibition of neurite outgrowth of PNS-neuron. Furthermore, since Semaphorin Z is a novel Semaphorin belonging to the Semaphorin family, it serves as an important research material or a laboratory reagent.

[0020] The present invention has been completed on the basis of the above findings.

[0021] That is, the gist of the present invention is as follows:

- (1) Semaphorin Z DNA comprising the nucleotide sequence shown in SEQ ID NO: 1 or 4;
- (2) Semaphorin Z open reading frame comprising the nucleotide sequence shown in SEQ ID NO: 2 or 5;
- (3) Semaphorin Z protein comprising the amino acid sequence shown in SEQ ID NO: 3 or 6;
- (4) DNA which encodes a protein having Semaphorin domain and which hybridizes under stringent conditions to DNA comprising the nucleotide sequence shown in SEQ ID NO: 7 ;
- (5) a protein encoded by the DNA of the above item (4);
- (6) DNA which encodes a protein inhibiting neurite outgrowth and which hybridizes under stringent conditions to the DNA of the above item (1);
- (7) DNA of the above item (6) which encodes a protein inhibiting neurite outgrowth of CNS-neuron;
- (8) a protein encoded by the DNA of the above item (6) or (7);
- (9) DNA which encodes a protein inhibiting neurite outgrowth, said protein containing insertions, deletions or substitutions of one or more amino acids in the protein of the above item (3);
- (10) DNA of the above item (9) which encodes a protein inhibiting neurite outgrowth of CNS-neuron;
- (11) a protein encoded by the DNA of the above item (9) or (10);
- (12) DNA which encodes a protein promoting neurite outgrowth of CNS-neuron, said protein containing insertions, deletions, or substitutions of one or more amino acids in the protein of the above item (3);
- (13) a protein encoded by the DNA of the above item (12);
- (14) DNA which is cloned from a human cDNA or genomic library, and which hybridizes under stringent conditions to DNA comprising at least part of the DNA of the above item (1) or at least part of the complementary strand thereof;
- (15) an expression plasmid expressing one of the DNAs of the above items (1), (2), (4), (6), (7), (9), (10), (12), or (14);
- (16) a transformant transformed with the expression plasmid of the above item (15);
- (17) a process for producing a recombinant protein, said process being characterized in that it comprises culturing the transformant of the above item (16) under conditions in which the expression plasmid of the above item (15) can be expressed;
- (18) a polypeptide comprising at least 6 amino acids of one of the proteins of the above items (3), (5), (8), (11), or (13);

(19) a polypeptide of the above item (18) which promotes neurite outgrowth of CNS-neuron;

(20) a polypeptide of the above item (18) characterized in that it contains aspartic acid residue at position 203 of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid residue corresponding to the position of said aspartic acid residue;

(21) DNA or RNA comprising 8 or more bases, or a chemically modified variant thereof, which has a sequence complementary to one of the DNAs of the above items (1), (4), (6), (7), or (14);

(22) DNA or RNA of the above item (21), or a chemically modified variant thereof, characterized in that it inhibits an expression of one of the proteins of the above items (3), (5), or (8);

(23) an antibody against one of the proteins of the above items (3), (5), (8), (11), or (13), or against one of the polypeptides of the above items (18) -(20);

(24) a screening method for Semaphorin Z inhibitor, which method is characterized in that it employs one of the proteins of the above items (3), (5), (8), or (11);

(25) Semaphorin Z inhibitor obtained by the screening method of the above item (24);

(26) Semaphorin Z inhibitor of the above item (25) which comprises the protein of the above item (13), the polypeptide of the above item (19) or (20), or the antibody of the above item (23);

(27) a CNS-neuron regeneration promoter which is characterized in that it contains at least one of the DNAs or RNAs of the above item (22) or chemically modified variants thereof, or Semaphorin Z inhibitors of the above item (25) or (26);

(28) a neurite outgrowth inhibitor for PNS-neuron which is characterized in that it contains at least one of the proteins of the above items (3), (5), (8), or (11); and

(29) a transgenic animal in which one of the DNAs of the above items (1), (4), (6), (7), (9), (10), or (12) has been artificially inserted into its chromosome, or has been knocked out.

MODE FOR CARRYING OUT THE INVENTION

[0022] The 1st embodiment of the present invention is cDNA for rat Semaphorin Z which comprises the base sequence shown in SEQ ID NO: 1 or cDNA for human Semaphorin Z which comprises the base sequence shown in SEQ ID NO: 4. These DNAs, as described in Example 1, may be cloned by screening a cDNA library derived from CNS tissue using a DNA having the sequence shown in SEQ ID NO: 7 as a probe. Particular techniques for such cloning may be found in a standard text such as *"Molecular Cloning, 2nd ed."*, Cold Spring Harbor Laboratory Press (1989). The nucleotide sequence of the cloned DNA may be determined by conventional methods, for example, using a sequence kit commercially available.

[0023] Alternatively, after publication of the nucleotide sequences of rat and human Semaphorin Z cDNAs of the present invention, one skilled in the art can also easily clone the rat and human Semaphorin Z gene in full length using part of said cDNA as a probe or primer, without using the cloning method as described above.

[0024] The 2nd embodiment of the present invention is an open reading frame of rat Semaphorin Z gene which comprises the nucleotide sequence shown in SEQ ID NO: 2 or an open reading frame of human Semaphorin Z gene which comprises the base sequence shown in SEQ ID NO: 5.

[0025] The 3rd embodiment of the present invention is a rat Semaphorin Z protein (referred to hereinafter simply as rat Semaphorin Z) which comprises the amino acid sequence shown in SEQ ID NO: 3 or a human Semaphorin Z protein (referred to hereinafter simply as human Semaphorin Z) which comprises the amino acid sequence shown in SEQ ID NO: 6.

[0026] Semaphorin Z contains Semaphorin domain characteristic to Semaphorins and this domain corresponds to a region extending from position 49 to position 580 of the amino acid sequence shown in SEQ ID NO: 3 or a region extending from position 48 to position 578 of the amino acid sequence shown in SEQ ID NO: 6.

[0027] Semaphorin Z also contains a signal sequence at its N-terminal and this sequence is presumed to correspond to a region from position 1 to position 26 of the amino acid sequence shown in SEQ ID NO: 3 or from position 1 to position 25 of the amino acid sequence shown in SEQ ID NO: 6. The signal sequence is removed by processing during its transfer to membrane.

[0028] Preparation of Semaphorin Z may be achieved, for example, by linking a cloned Semaphorin Z cDNA to a known expression vector such as pET or pCDM8, and introducing the vector into an appropriate host cell to express and produce Semaphorin Z. The host cell may be procaryotic or eukaryotic. For example, *Escherichia coli* strains or animal cell lines are already conventionally used for such purpose and they are commercially available. Examples of animal host cells include COS-1, COS-7, CHO cells and the like.

[0029] To transform an appropriate animal host cell with an expression plasmid, a known procedure such as the DEAE-dextran method (*Current Protocols in Molecular Biology*, F. M. Ausubel *et al.* ed., John Wiley & Sons (1987)) may be used. As demonstrated in Example 7, Semaphorin Z of the present invention is localized in the cell membrane fraction which contains a sufficient amount of Semaphorin Z to be directly used in various assays. Therefore, various

assays for Semaphorin Z activity may easily be conducted using the cell membrane fraction.

[0030] The cell membrane fraction may easily be prepared by homogenizing Semaphorin Z-expressing cells, isolating and purifying the fraction by centrifugation as described hereinafter in Example 7.

[0031] Semaphorin Z may be purified by, for example, an affinity purification using an antibody against Semaphorin Z described hereinafter in the section of the 23rd embodiment of the present invention, or conventional column chromatography.

[0032] The 4th embodiment of the present invention is a DNA which encodes a protein having semaphorin domain and which hybridizes under stringent conditions to DNA comprising the nucleotide sequence shown in SEQ ID NO: 7.

[0033] In the above description, "DNA comprising the nucleotide sequence shown in SEQ ID NO: 7" refers to a fragment cloned from cDNA by PCR reaction using the sequence information of the DNA "T08532" which encodes, in a part, a sequence (Gln-Asp-Pro-Tyr-Cys-Gly-Trp-Ala) similar to the eight amino-acid sequence well conserved among Semaphorins (Gln (or Arg)-Asp-Pro-Tyr (or His)-Cys-Ala (or Gly)-Trp-Asp). The DNA fragment corresponds to a region from position 1510 to position 1685 in the nucleotide sequence of rat Semaphorin Z shown in SEQ ID NO: 1, or a region from position 1524 to position 1699 in the nucleotide sequence of human Semaphorin Z shown in SEQ ID NO: 4.

[0034] As used herein, DNA which "hybridizes under stringent conditions" refers to such a DNA that hybridizes to DNA of SEQ ID NO: 7, for example, when hybridized under the following conditions: a formamide concentration of about 45% (v/v), a salt concentration of about 5x SSPE, and a temperature of about 42°C, and washed under the following conditions: a salt concentration of 2x SSPE, and a temperature of about 42°C, as described in Example 1.

[0035] Cloning of these DNAs is achieved by, for example, hybridization with DNA of SEQ ID NO: 7, and specifically may be carried out, for example, according to the procedures described in *TINS*, 15, 319-323 (1992) and references cited therein, and more specifically according to the following procedures.

[0036] That is, the cloning may be achieved by screening a cDNA or genomic library prepared from one of various animal tissues using DNA consisting of the nucleotide sequence shown in SEQ ID NO: 7 as a probe. The screening may be carried out according to, for example, the procedures as described in Example 1. Preferred cDNA libraries are those derived from an adult tissue of CNS, and a cDNA library derived from hippocampus, corpus striatum, or cerebellum is more preferred. As described above, the conditions shown in Example 1 or those described in *TINS*, 15, 319-323 (1992) and references cited therein may be used for the hybridization.

[0037] The DNA of the 4th embodiment of the present invention is also "DNA which encodes a protein having semaphorin domain". As used herein, "semaphorin domain" refers to a domain consisting of 300-600 amino acid residues more than 20% of which are identical to those amino acid residues constituting semaphorin domain of one of 10 known Semaphorins (G-Sema I, T-Sema, I, D-Sema II, H-Sema III, C-Collapsin, Sem A, Sem B, Sem C, Sem D, Sem E) described in, for example, *Cell*, 75, 1389-1399 (1993) or *Neuron*, 14, 941-948 (1995). Those proteins having semaphorin domain more than 30% of which amino acids are identical to those amino acids of one of the known Semaphorins are particularly preferred. The identity of amino acids is determined by comparison using, for example: DNASIS Ver. 2.0 (HITACH Software Engineering) under conditions of ktup=1 and cutoff=1. More preferred proteins are those in which 10 or more cysteines, particularly 12 or more cysteines, of the 13 cysteines conserved in Semaphorin domains of the 10 known Semaphorins (for example, those cysteines marked in Figure 1 on page 942 of *Neuron*, 14, 941-948 (1995)) are conserved.

[0038] Specific examples of DNA of the 4th embodiment of the present invention may include unknown Semaphorin genes which hybridizes under stringent conditions to DNA comprising the nucleotide sequence shown in SEQ ID NO: 7, including all the Semaphorin Z genes of mammal and avian. Between mammals or between mammal and avian, homologous genes have quite similar sequences, and usually more than 75%, in many cases more than 90%, of the base sequence are common each other. Therefore, all the Semaphorin Z genes of mammal and avian are included within the 4th embodiment of the present invention.

[0039] The 5th embodiment of the present invention is a protein encoded by DNA of the 4th embodiment of the present invention. Specifically, this embodiment is a protein which is encoded by DNA hybridizing under stringent conditions to DNA comprising the nucleotide sequence shown in SEQ ID NO: 7, and contains Semaphorin domain. These proteins can be expressed and purified by the methods similar to those used for a protein of the 3rd embodiment of the present invention.

[0040] These DNAs of the 4th embodiment of the present invention and the proteins of the 5th embodiment of the present invention can be achieved thanks to the discovery of Semaphorin Z which forms the core of the present invention. Once Semaphorin Z has been discovered, one can easily clone DNA of the 4th embodiment of the present invention and express a protein of the 5th embodiment of the present invention, according to conventional methods as described above. Therefore, DNAs of the 4th embodiment of the present invention and proteins of the 5th embodiment of the present invention both of which are found concomitantly with the discovery of Semaphorin Z also retain the essence of the present invention, and are thus included within the scope of the present invention.

[0041] The 6th embodiment of the present invention is DNA which encodes a protein inhibiting neurite outgrowth and which hybridizes under stringent conditions to DNA of the 1st embodiment of the present invention (rat and human

Semaphorin Z DNA).

[0042] The DNA mentioned above hybridizes to DNA shown in SEQ ID NO: 1 or 4, and can be cloned, for example, by screening a cDNA or genomic library prepared from one of various animal tissues using DNA shown in SEQ ID NO: 1 or 4 as a whole or in part as a probe. Particular methods for screening and the like may be similar to those used for DNA of the 4th embodiment of the present invention. The "stringent conditions" used herein may also be similar to those used for DNA of the 4th embodiment of the present invention.

[0043] The phrase "inhibiting neurite outgrowth" means that the protein has a collapse activity on growth cone of neuron as demonstrated in Example 8, or that the protein has a neurite-outgrowth inhibition activity. These activities may be measured using, for example, an expression product which is obtained by expressing said DNA by the methods similar to those used for expressing a protein of the 3rd embodiment of the present invention, and, for example, in the following manner:

[0044] Since Semaphorin Z is a membrane protein as confirmed in Example 7, activities of Semaphorin Z can easily be measured by using, as a test material, a membrane fraction of cells transformed with Semaphorin Z gene (see Example 8).

[0045] Activities of Semaphorin Z can be measured by various methods, and representative methods include, for example, those for a collapse activity on growth cone of neuron (M. Igarashi *et al.*, *Science*, vol. 259, pp. 77-79 (1993)) or a neurite-outgrowth inhibition activity (J. A. Davies *et al.*, *Neuron*, vol. 2, pp. 11-20 (1990); M. Bastmeyer, *J. Neurosci.*, vol. 11, pp. 626-640 (1991)). A method of measuring a growth-cone collapse activity is described in detail in the paper (M. Igarashi *et al.*, *Science*, vol. 259, pp. 77-79 (1993)). Briefly, the measurement may be carried out by a method in which cells expressing Semaphorin Z is homogenized, and the homogenate containing the cell membrane fraction or the purified membrane fraction is used (E. C. Cox *et al.*, *Neuron*, vol. 2, pp. 31-37 (1990)), or by a method in which a protein extracted from the membrane fraction is reconstituted in a liposome and used as a test material (C. E. Bandtlow, *Science*, vol. 259, pp. 80-84 (1993)). To measure a growth-cone collapse activity using these materials, Semaphorin Z protein in one of the foregoing forms is added to neurons cultured under usual conditions (see, for example, "Culturing, Nerve Cells" edited by Banker *et al.*, MIT Press (1991)) in a container coated with a substance promoting the neurite outgrowth and the growth-cone formation, such as laminin, collagen, polylysine or polyornithine. When sufficient time has passed to occur a collapse of growth cone (typically from 30 minutes to one hour after the addition), those neurons are fixed with 1% glutaraldehyde or the like, and the number of the growth cones which have been collapsed is counted under a microscope. In this measurement, it is important that another sample is used as a control, which is prepared from cells not-expressing Semaphorin Z according to the completely same procedures as those used for Semaphorin Z-expressing cells. Typically, normalization of the samples is conducted on the basis of the total amounts of protein included within the samples. To measure a neurite-outgrowth inhibition activity, part of the surface of a micropore filter or a culture container made of glass or plastics is coated with Semaphorin Z prepared as described above. The activity may be indicated, for example, by the inability of neurons cultured under usual conditions to adhere to the coated area, or a remarkable decrease in the rate of neurite outgrowth on the coated area, or the inability of invasion of growing neurites from the outside of the coated area into the coated area because of its stopping on the border between the coated and non-coated areas or its avoidance from the coated area. When a cluster of cells expressing Semaphorin Z is co-cultured with neurons in a collagen gel, the inability of outgrowing neurite to enter the cluster of cells expressing Semaphorin Z may also be used as an indicator (A. Sophia *et al.*, *Cell*, vol. 81, 621-629 (1995)).

[0046] Specific examples of such DNAs of the 6th embodiment of the present invention, as well as examples of DNAs of the 7th embodiment of the present invention, may include, for example, all the Semaphorin Z genes of mammal and avian.

[0047] The 7th embodiment of the present invention is DNA of the 6th embodiment of the present invention which encodes a protein inhibiting neurite outgrowth of CNS-neuron.

[0048] In this context, the phrase "inhibiting neurite outgrowth of CNS-neuron" means that the protein has the activity of Semaphorin Z of the present invention, and this activity may be measured by using CNS-neuron as a cell for assay in the measurement described above in connection with the 6th embodiment of the present invention.

[0049] As described in the "Prior Art" section, CNS in adult mammals naturally contains a large amount of regeneration (outgrowth) inhibitor. It is, therefore, extremely difficult to measure *in vivo* an inhibitory effect on neurite outgrowth of CNS-neuron, and such inhibitory effect is usually measured by an *in vitro* method as described above in connection with the 6th embodiment of the present invention. Since these *in vitro* methods each have an individual characteristic, it is preferred to use more than one method to confirm the activity. Although preferred neurons used for a measurement of the activity are CNS-neurons such as spinal cord or motor neuron in motor cortex, PNS-neurons in superior cervical ganglion and dorsal root ganglion (DRG) may also be used because NI35/250 known as a CNS-neuron regeneration inhibitor has proved to have neurite-growth inhibition and growth-cone collapse activity also on these PNS-neurons (*J. Cell Biol.*, 106, 1281-1288 (1988), *Science*, 259, 80-83 (1993)).

[0050] The 8th embodiment of the present invention is a protein encoded by DNA of the 6th or 7th embodiment of the present invention. Specifically, it is a protein which is encoded by DNA hybridizing under stringent conditions to DNA of

the 1st embodiment of the present invention and which protein inhibits neurite outgrowth or which protein inhibits neurite outgrowth of CNS-neuron. These proteins can be expressed and purified by the methods similar to those used for a protein of the 3rd embodiment of the present invention. The activity may be measured by the methods described above in connection with the 6th and 7th embodiments of the present invention.

[0051] DNAs of the 6th and 7th embodiments of the present invention and the proteins of the 8th embodiment of the present invention can be achieved entirely thanks to the discovery of Semaphorin Z which forms the core of the present invention. Once Semaphorin Z has been found, one can easily clone and express DNA of the 6th or 7th embodiment of the present invention by conventional methods as described above. The protein of the 8th embodiment of the present invention having said activity can be then identified by subjecting the expression product thus obtained to an activity measurement system as described above. Therefore, DNAs of the 6th and 7th embodiments of the present invention and the proteins of the 8th embodiment of the present invention, both of which are easily found concomitantly with the discovery of Semaphorin Z, also retain the essence of the present invention, and are thus included within the scope of the present invention.

[0052] The 9th embodiment of the present invention is DNA which encodes a protein inhibiting neurite outgrowth, said protein containing insertions, deletions, or substitutions of one or more amino acids in the rat and human Semaphorin Zs of the 3rd embodiment of the present invention. The 10th embodiment of the present invention is DNA of the 9th embodiment of the present invention which encodes a protein inhibiting neurite outgrowth of CNS-neuron.

[0053] In this connection, one skilled in the art can easily introduce "an insertion, deletion, or substitution of one or more amino acids" by, for example, a site-directed mutagenesis (*Methods in Enzymology*, 100, 448- (1993)) or a PCR method (*Molecular Cloning*, 2nd ed., Chapter 15, Cold Spring Harbor Laboratory Press (1989), "PCR A Practical Approach" IRL Press, 200-210 (1991)). The inhibitory effect on neurite outgrowth can be measured by the methods described above in connection with the 6th and 7th embodiments of the present invention.

[0054] Based on the structural comparison of known Semaphorins, most of the conserved amino acids are located in Semaphorin domain, suggesting that these conserved amino acids are essential for expression of the activity of Semaphorin. Furthermore, the present inventors has found that a modified Sema III protein in which the aspartic acid residue at position 198 in its Semaphorin domain has been substituted with glycine does not have a growth-cone collapse activity (see Reference example 1 below). Accordingly, the aspartic acid at position 198 of Sema III is believed essential for expression of the activity. The amino acid residues corresponding to this position are highly conserved in known Semaphorins, and they are all aspartic acid with a few exceptions in which glutamic acid is located at this position. It is, therefore, believed that the amino acid residue at this position is also essential for expression of the activity of Semaphorins other than Sema III. In Semaphorin Z of the present invention, the amino acid residue corresponding to the position 198 of Sema III is presumed to be the aspartic acid at position 204 in the amino acid sequence of rat Semaphorin Z shown in SEQ ID NO: 3 or the aspartic acid at position 203 in the amino acid sequence of human Semaphorin Z shown in SEQ ID NO: 6.

[0055] Considering the above information, it is desirable to introduce insertions, deletions, or substitutions of one or more amino acids into the amino acid sequence not containing the residues conserved among Semaphorins, so as to retain the activity of Semaphorin Z in the modified protein (a protein encoded by DNA of the 9th or 10th embodiment of the present invention). Particularly, it is desirable not to modify the aspartic acid at position 204 in rat Semaphorin Z shown in SEQ ID NO: 3 and the aspartic acid at position 203 in human Semaphorin Z. In order to substitute an amino acid conserved among Semaphorins while retaining the activity of Semaphorin Z, it is desirable to substitute an amino acid having a similar side chain for the amino acid to be substituted. By substituting such amino acid having a similar side chain for a conserved amino acid, it may be possible to produce a modified protein which has an enhanced activity of Semaphorin Z. Such modified protein having an enhanced activity is highly suitable as a neurite-outgrowth inhibitor for PNS-neuron as will be described below in connection with the 28th embodiment of the present invention.

[0056] In the above-noted embodiment, "a conserved amino acid" refers to an amino acid located at a position at which more than 50% of Semaphorin genes shown in Fig. 2 of *Cell*, 75, 1389-1399 (1993) or Fig. 1 of *Neuron*, 14, 941-948 (1995) share the same amino acid.

[0057] The 11th embodiment of the present invention is a protein encoded by DNA of the 9th or 10th embodiment of the present invention. Specifically, the protein is a so-called "modified protein" which contains insertions, deletions, or substitutions of one or more amino acid in a protein of the 3rd embodiment of the present invention, and which inhibits neurite outgrowth or which inhibits neurite outgrowth of CNS-neuron. These proteins can be expressed and purified by the methods similar to those used for the protein of the 3rd embodiment of the present invention. The activity may be measured by the methods described above in connection with the 6th and 7th embodiments of the present invention.

[0058] DNAs of the 9th and 10th embodiments of the present invention and the proteins of the 11th embodiment of the present invention can be achieved entirely thanks to the discovery of Semaphorin Z which forms the core of the present invention. Once Semaphorin Z has been found, one can introduce therein insertions, deletions, or substitutions of one or more amino acids by the conventional methods as described above, and one can identify the protein of the 11th embodiment of the present invention by subjecting the modified protein thus obtained to an activity measurement

system as described above. Therefore, DNAs of the 9th and 10th embodiments of the present invention and the proteins of the 11th embodiment of the present invention, both of which are easily attained concomitantly with the discovery of Semaphorin Z, also retain the essence of the present invention, and are thus included within the scope of the present invention.

5 [0059] The 12th embodiment of the present invention is DNA encoding a protein which contains insertions, deletions, or substitutions of one or more amino acids in rat or human Semaphorin of the 3rd embodiment of the present invention, and which protein promotes neurite outgrowth of CNS-neuron.

[0060] The insertion, deletion, and substitution in these DNAs can be introduced therein according to the procedures similar to those used for DNA of the 9th embodiment of the present invention. The activity which promotes neurite out-
10 growth of CNS-neuron can easily be measured by, for example, adding a test material (*i.e.*, a modified Semaphorin Z protein as a candidate) to an assay system for the activity described above in connection with the 6th and 7th embodiments of the present invention. For details, see the descriptions of the 24th embodiment of the present invention.

[0061] A specific example of these proteins may be a modified Semaphorin Z protein of which neurite-outgrowth inhibition activity on CNS-neuron has been inactivated. When the modified protein which does not have such inhibition
15 activity binds to a receptor for Semaphorin Z or to Semaphorin Z itself, the neurite-outgrowth promotion effect on CNS-neuron will arise. As described above in connection with the 9th embodiment of the present invention, it has been suggested that the active site of Semaphorin may be located in Semaphorin domain, and particularly, it may be located at the aspartic acid at position 204 in rat Semaphorin Z or the aspartic acid at position 203 in human Semaphorin Z. Accordingly, in order to eliminate the Semaphorin Z activity, it is desirable to conduct insertions, deletions or substitu-
20 tions of one or more amino acids at the conserved amino acid(s) in said Semaphorin domain, preferably directed to the aspartic acid at position 204 in rat Semaphorin Z or to the aspartic acid at position 203 in human Semaphorin Z. In such cases, those substitutions in which an amino acid having a side chain of a distinct nature is substituted for the original amino acid are desirable.

[0062] Since the protein encoded by DNA of the 12th embodiment of the present invention promotes neurite out-
25 growth of CNS-neuron as described above, it serves as a regeneration promoter for CNS-neuron as described below in connection with the 27th embodiment of the present invention.

[0063] The 13th embodiment of the present invention is a protein encoded by DNA of the 12th embodiment of the present invention. Specifically, it is a protein which contains insertions, deletions, or substitutions of one or more amino acids in the protein of the 3rd embodiment of the protein invention, and which promotes neurite outgrowth of CNS-neu-
30 ron. These proteins can be expressed and purified by the methods similar to those used for the protein of the 3rd embodiment of the present invention. The neurite-outgrowth promotion effect on CNS-neuron may be measured by the methods described above in connection with the 12th embodiment of the present invention.

[0064] These DNAs of the 12th embodiment of the present invention and the proteins of the 13th embodiment of the present invention can be achieved entirely thanks to the discovery of Semaphorin Z which forms the core of the present
35 invention. Once Semaphorin Z has been found, one can produce a modified protein in which insertions, deletions, or substitutions have been introduced by the conventional methods as described above, and one can easily identify the modified protein having a neurite-outgrowth promotion activity by subjecting it to a measurement system (screening system) for such activity as described above. DNAs of the 12th embodiment of the present invention and the proteins of the 13th embodiment of the present invention, both of which are easily attained concomitantly with the discovery of
40 Semaphorin Z, also retain the essence of the present invention, and are thus included within the scope of the present invention.

[0065] The 14th embodiment of the present invention is DNA which is cloned from a human cDNA or genomic library and which hybridizes under stringent conditions to DNA comprising at least part of rat or human Semaphorin Z DNA of the 1st embodiment of the present invention or at least part of the complementary strand thereof.

45 [0066] Methods of Cloning are described in detail in, for example, "*Molecular Cloning 2nd ed.*", Cold Spring Harbor Laboratory Press (1989), and specifically include, for example, methods employing hybridization or PCR reaction. Although a preferred library used herein is a genomic library derived from human, a cDNA library derived from CNS-neuron in the adult may also be used. Those methods employing hybridization may be carried out according to, for example, *TINS*, 15, 319-323 (1992) and references cited therein. Those methods employing PCR may be carried out
50 according to, for example, "*PCR*", edited by McPherson *et al.* ed., 1991, IRL Press.

[0067] The DNA thus cloned is a gene for human Semaphorin Z, and such DNAs include not only the full length DNA but also its DNA fragments comprising more than 200 bases. Specific examples of DNA of the 14th embodiment of the present invention may include chromosomal DNAs containing 5' and/or 3' transcriptional control regions, noncoding regions of exons, introns, or the like, in addition to those consisting of a region encoding amino acids. Such sequences
55 which do not encode any amino acids are also quite useful, for example, when it is desired to develop a medicine using antisense techniques described below.

[0068] Since these DNAs of the 14th embodiment of the present invention are also easily achieved concomitantly with the discovery of Semaphorin Z, it goes without saying that they are included within the scope of the present invention.

[0069] The 15th embodiment of the present invention is an expression plasmid expressing one of DNAs of the 1st, 2nd, 4th, 6th, 7th, 9th, 10th, 12th, and 14th embodiments of the present invention. The 16th embodiment of the present invention is a transformant transformed with said expression plasmid. The 17th embodiment of the present invention is a process for producing a recombinant protein which process is characterized in that it comprises culturing said transformant under conditions in which said expression plasmid can be expressed. As described above in connection with the 3rd embodiment of the present invention, methods of preparing an expression plasmid and a transformant, and methods of producing a recombinant protein, *per se*, are all well known to those skilled in the art.

[0070] The 18th embodiment of the present invention is a polypeptide comprising at least 6 amino acids of one of the proteins of the 3rd, 5th, 8th, 11th, and 13th embodiments of the present invention. In this connection, the limitation "at least 6 amino acids" is based on the fact that a minimal size of polypeptide capable of forming a stable structure consists of 6 amino acids, and preferred polypeptides are those consisting of 10-20 amino acids. A short polypeptide such as those consisting of 10-20 amino acids can be synthesized on a peptide synthesizer, while a longer polypeptide can be obtained by preparing DNA through usual genetic engineering, and expressing it in, for example, an animal cell as described above. The polypeptide thus prepared can also be modified by usual methods.

[0071] These polypeptides can be applied to medicaments as described below in connection with the 19th and 20th embodiments of the present invention and can also be used for producing antibodies.

[0072] The 19th embodiment of the present invention is a polypeptide of the 18th embodiment of the present invention which promotes neurite outgrowth of CNS-neuron. Such polypeptide may be prepared by the methods described above in connection with the 18th embodiment of the present invention. The promotion effect on neurite outgrowth of CNS-neuron can easily be measured as described above in connection with the 12th embodiment of the present invention by adding a test substance (*i.e.*, a polypeptide derived from Semaphorin Z as a candidate) to an activity measurement system described above in connection with the 6th and 7th embodiments of the present invention. For details, see the descriptions of the 24th embodiment of the present invention.

[0073] A specific example of these polypeptides may be a Semaphorin Z polypeptide of which neurite-outgrowth inhibition activity on CNS-neuron has been lost. When a polypeptide which does not have such inhibition activity bind to a receptor for Semaphorin Z or to Semaphorin Z itself, the neurite-outgrowth promotion effect on CNS-neuron will arise. As described below in connection with the 27th embodiment of the present invention, such polypeptide may serve as a CNS-neuron regeneration promoter.

[0074] The 20th embodiment of the present invention is a polypeptide of the 18th embodiment of the present invention characterized in that it contains aspartic acid residue at position 203 of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid corresponding to the position of said aspartic acid residue. Such polypeptide may be prepared by the methods described above in connection with the 18th embodiment of the present invention.

[0075] As described above in connection with the 9th embodiment of the present inventions, the aspartic acid residue at position 203 of human Semaphorin Z shown in SEQ ID NO: 6 (in the case of rat, the aspartic acid at position 204) seems essential for expression of the activity of Semaphorin Z. Since this amino acid may possibly be involved in the binding between Semaphorin Z and Semaphorin Z receptor, a polypeptide of the 20th embodiment of the present invention containing this amino acid residue may interfere with the neurite-outgrowth inhibition activity on CNS-neuron exerted by Semaphorin Z, by binding to the receptor for Semaphorin Z or to Semaphorin Z itself, resulting in promotion of neurite outgrowth of CNS-neuron. A polypeptide having such effect may serve as a CNS-neuron regeneration promoter as described below in connection with the 27th embodiment of the present invention. Such neurite-outgrowth promotion activity on CNS-neuron can easily be measured as described above in connection with the 12th embodiment of the present invention by adding a test substance (*i.e.*, a polypeptide derived from Semaphorin Z polypeptide as a candidate) to an activity measurement system described above in connection with the 6th and 7th embodiments of the present invention. For details, see the descriptions of the 24th embodiment of the present invention.

[0076] In the above-noted embodiment, "an amino acid corresponding to the position of said aspartic acid" refers to an amino acid which is located at the position corresponding to position 203 in human Semaphorin Z, when the amino acid sequence of the protein of the 5th, 8th, 11th, or 13th embodiment of the present invention is aligned with the amino acid sequence shown in SEQ ID NO: 6 so that a maximal identity is obtained. Accordingly, "a polypeptide characterized in that it contains an amino acid corresponding to the position of said aspartic acid" refers to a polypeptide which comprises such amino acid at the position corresponding to position 203 of human Semaphorin Z as well as a few amino acids contiguous to said amino acid.

[0077] The 21st embodiment of the present invention is DNA or RNA comprising 8 or more bases, or a chemically modified variant thereof, which has a sequence complementary to one of the DNAs of the 1st, 4th, 6th, 7th, and 14th embodiments of the present invention.

[0078] In this context, "DNA or RNA which has a sequence complementary to..." (referred to hereinafter as "antisense nucleotide") is a so-called antisense oligonucleotide, antisense RNA, or antisense DNA, and it may be artificially prepared using a DNA synthesizer, or may be obtained by, for example, expressing a gene in the direction opposite to the usual case (*i.e.*, in the antisense direction) as described below in Example 9. For details, see the descriptions of the

27th embodiment of the present invention.

[0079] These antisense nucleotides are used for inhibiting the expression of Semaphorin Z as described below in connection with the 22nd embodiment of the present invention. In addition, they are also useful as laboratory reagents for, for instance, *in situ* hybridization. In this embodiment, "a chemically modified variant" specifically refers to such a variant that is chemically modified so as to enhance the transferability of the antisense oligonucleotide into cells or the stability of the antisense oligonucleotide in the cells. Examples of such chemically modified variant are phosphorothioate, phosphorodithioate, alkylphosphotriester, alkyl phosphonate, alkyl phosphoramidate, and the like derivatives ("*Antisense RNA and DNA*", WILEY-LISS, 1992, pp. 1-50, *J. Med. Chem.*, 36, 1923-1937 (1993)). These chemically modified variant may be prepared according to, for example, the above-mentioned papers.

[0080] The 22nd embodiment of the present invention is DNA or RNA of the 21st embodiment of the present invention, or a chemically modified variant thereof, which is characterized in that it inhibits the expression of one of the proteins of the 3rd, 5th, and 8th embodiment of the present invention.

[0081] A mRNA produced by usual gene transcription is a sense-strand. The antisense nucleotides, that is, antisense oligonucleotide and antisense DNA or RNA, or chemically modified variants thereof can bind to the sense-strand mRNA in cells to inhibit the expression of that particular gene. Therefore, the above-described antisense nucleotides or chemically modified variants thereof can inhibit the expression of Semaphorin Z of, for example, the 3rd embodiment of the present invention, thereby inhibiting the activity of said Semaphorin Z. Antisense nucleotides or chemically modified variants thereof having such effect serve as CNS-neuron regeneration promoters as described below in connection with the 27th embodiment of the present invention.

[0082] It can easily be determined whether a particular antisense nucleotide prepared, or a chemically modified variant thereof has a desired inhibitory effect or not, by directly introducing the antisense oligonucleotide itself or, as will be described below in Example 11, introducing a gene which produces said antisense RNA when transcribed, into a cell expressing Semaphorin Z, and then determining whether the amount of the expressed Semaphorin Z is decreased or not.

[0083] Examples of an antisense nucleotide exhibiting such inhibitory effect may be those having sequences complementary to the coding region or the 5' or 3' noncoding region of Semaphorin cDNA of the above-described embodiments. Especially preferred are those having sequences complementary to the transcription initiation site, translation initiation site, 5' noncoding region, exon-intron junction region, or 5' CAP region. As described in Example 11, an antisense RNA for Semaphorin Z of the present invention has been confirmed to inhibit the expression of Semaphorin Z. Therefore, it may serve as a CNS-neuron regeneration promoter of the 27th embodiment of the present invention described below.

[0084] The 23rd embodiment of the present invention is an antibody against one of the proteins of the 3rd, 5th, 8th, 11th, and 13th embodiments of the present invention or against one of the polypeptides of the 18th-20th embodiments of the present invention. Such antibody can easily be produced by immunizing a mouse or rabbit against a recombinant Semaphorin Z protein of claim 17 or a peptide of claim 18, according to the procedures described in, for example, *Current Protocols in Immunology*, pp. 2.4.1-2.6.6 (1992, J. E. Coligan ed.). Monoclonal antibodies can also easily be produced by the methods described in the above-mentioned reference. Such antibodies may be used in affinity chromatographies or screening of cDNA libraries, and as a pharmaceutical or diagnostic agent, or a laboratory reagent. Some of such antibodies can neutralize the activity of Semaphorin Z. These neutralizing antibodies can easily be identified as described above in connection with the 12th embodiment of the present invention by adding a test substance (*i.e.*, a candidate antibody against Semaphorin Z) to an activity measurement system described above in connection with the 6th and 7th embodiments of the present invention. As described below in connection with the 27th embodiment of the present invention, such neutralizing antibody may serve as a CNS-neuron regeneration promoter.

[0085] One skilled in the art can easily prepare the above-described polypeptide of the 18th-20th embodiments of the present invention, DNA or RNA of the 21st or 22nd embodiment of the present invention or chemically modified variant thereof, and the antibody of the 23rd embodiment of the present invention, only if Semaphorin Z has been discovered. In addition, as described above, the state of the art allows one skilled in the art to easily determine whether or not such substances have particular functions such as neurite-outgrowth promotion effect on CNS-neuron. Accordingly, these substances are all included within the scope of the present invention.

[0086] The 24th embodiment of the present invention is a screening method for Semaphorin Z inhibitors, which method is characterized in that it employs one of the proteins of the 3rd, 5th, 8th, and 11th embodiments of the present invention. As used herein, "Semaphorin Z inhibitor" refers to a substance which inhibits, for example, the neurite-outgrowth inhibition activity on CNS-neuron exerted by Semaphorin Z.

[0087] The screening is conducted by adding a test substance to a Semaphorin Z activity measurement system described above in connection with the 6th and 7th embodiments of the present invention. Specifically, inhibition of the Semaphorin Z activity resulted from the addition of the test substance to the culture medium throughout the incubation period or only temporarily in the incubation period can be used as an indicator in the Semaphorin Z activity measurement. It is also important to confirm that the test substance alone does not influence the survival and neurite-outgrowth

of neurons at the same concentration. When both of these requirements are fulfilled, one can consider the test substance as a Semaphorin Z inhibitor. Although it is preferred to prepare in advance the test substance in the form of aqueous solution, an organic solvent such as DMSO may also be used as a solvent. In any cases, it is important to minimize the volume of the solvent so as to exclude any effects of the solvent on neurons. Specifically, the volume to be added should be less than an equal volume, preferably less than 1/10 volume, and more preferably less than 1/100 volume relative to the culture medium. Semaphorin Z inhibitor thus obtained may be used as a CNS-neuron regeneration promoter as described below in connection with the 27th embodiment of the present invention.

[0088] The 25th embodiment of the present invention is Semaphorin Z inhibitor which is obtained by the screening method of the 24th embodiment of the present invention. The inhibitor may have any structure and any form, provided that it inhibits the activity of Semaphorin Z.

[0089] The 26th embodiment of the present invention is Semaphorin Z inhibitor of the 25th embodiment which comprises the protein of the 13th embodiment of the present invention, the polypeptide of the 19th or 20th embodiment of the present invention, or the antibody of the 23rd embodiment of the present invention. Specifically, it comprises the protein of the 13th embodiment, the polypeptide of the 19th or 20th embodiment, or the antibody of the 23rd embodiment of the present invention which inhibits the activity of Semaphorin Z. The inhibitors can easily be selected by conducting the screening of the 24th embodiment of the present invention, and the inhibitors thus selected may serve as a CNS-neuron regeneration promoter as described below in the 27th embodiment of the present invention.

[0090] The 27th embodiment of the present invention is a CNS-neuron regeneration promoter characterized in that it comprises at least one of DNAs or RNAs of the 22nd embodiment of the present invention, or chemically modified variants thereof, or at least one of Semaphorin Z inhibitors of the 25th or 26th embodiment of the present invention. This embodiment relates to the use of substances for "promotion of CNS-neuron regeneration". The following descriptions explain the use, dose and the like, of the substances.

1) Antisense nucleotide or its chemically modified variant

[0091] As described above in connection with the 22nd embodiment of the present invention, the antisense nucleotide of the 22nd embodiment or its chemically modified variant can inhibit the expression of Semaphorin Z gene. Accordingly, such antisense nucleotide may decrease the abundance of the Semaphorin protein, and promote the regeneration of CNS-neuron. Therapeutic methods using the nucleotide or the variant include those in which the antisense oligonucleotide or its chemically modified variant itself is administered, and those in which antisense RNA is produced in cells.

[0092] In the method in which the antisense oligonucleotide or its chemically modified variant itself is administered, a preferred antisense oligonucleotide has a length of, for example, about 8-200 bases, and more preferably 8-25 bases, and especially preferably 12-25 bases. Antisense oligonucleotide or its chemically modified variant may be formulated by mixing it with stabilizing agent, buffer, solvent and the like prior to its administration. Such formulation may be co-administered with, for example, an antibiotic, anti-inflammatory, or anesthetic agent. Although the formulation thus prepared may be administered via various routes, it is preferred to topically administered at a site in which neurons are notably disordered. Usually, the regeneration of neuron takes several days to several months, and the formulation is administered every day, or every several days to several weeks. To avoid such frequent administrations, a sustained-release mini-pellet formulation may be prepared and embedded near the affected site. Alternatively, a formulation may be gradually and continuously administered to the affected site by means of, for example, an osmotic pump. Typically, the dose is adjusted so that the concentration at the site of action will be 0.1 nM-10 μ M.

[0093] In the method in which an antisense RNA is produced in a cell, a preferred antisense RNA has a length of, for example, more than 100 bases, preferably more than 300 bases, and more preferably more than 500 bases.

[0094] The methods by which a gene expressing an antisense RNA is introduced into a patient include an *in vivo* method in which the gene is directly introduced into a cell in a living body, and an *ex vivo* method in which the gene is introduced into a particular cell *ex vivo* and the cell is returned into the body (Nikkei Science, April, 1994, pp. 20-45; Gekkan-Yakuji, 36 (1), 23-48 (1994); Jikkenn-Igaku-Zokan, 12 (15), 1994; and references cited therein). An *in vivo* method is more preferred.

[0095] Such *in vivo* methods include a method employing recombinant viruses and other methods (Nikkei Science, April, 1994, pp. 20-45; Gekkan-Yakuji, 36 (1), 23-48 (1994); Jikken-Igaku-Zokan, 12 (15), in its entirety (1994); and references cited therein).

[0096] The methods employing recombinant viruses may include the methods in which Semaphorin gene is incorporated into a virus genome of, for example, retrovirus, adenovirus, adeno-associated virus (AAV), herpesvirus, vaccinia virus, poliovirus, or sindbis virus, and the virus is introduced into a living body. Among these methods, those employing retrovirus, adenovirus or adeno-associated virus are particularly preferred.

[0097] Other methods may include a liposome method or a lipofectin method. The liposome method is particularly preferred.

[0098] The *ex vivo* methods which may be used include, besides those described above, a micro-injection method, a calcium phosphate method, electroporation and the like.

[0099] Administration of the gene to a patient is carried out via appropriate routes depending on particular disease or symptom to be treated, and the like. For example, it may be administered intravenously, intraarterially, subcutaneously, or intramuscularly, or directly administered into an affected site such as neuron. For example, when spinal cord is infected with the recombinant viruses, the expression of Semaphorin gene is inhibited exclusively in the spinal cord. Usually, the expression of antisense RNA lasts several days to several months, and such single infection is sufficient to allow the regeneration of neuron. When expressed insufficiently, the gene may be re-introduced. When administered by an *in vivo* method, the gene may be formulated in the form of, for example, a solution, and typically it is formulated in the form of an injection containing Semaphorin gene as an active ingredient to which conventional carrier and the like may be added, if necessary. In the case of liposomes or membrane-fused liposomes (such as Sendai virus (HVJ)-liposomes) containing Semaphorin gene, the liposome preparations may be in the form of a suspension, a frozen preparation, a centrifugally-concentrated frozen preparation or the like.

[0100] Although the amount of Semaphorin gene in the formulation may vary depending on the disease to be treated, the age and weight of the patient, and the like, it is typically 0.0001-100 mg, and preferably 0.001-10 mg, and such formulation is preferably administered once every several days to several months.

2) Modified protein of Semaphorin Z

[0101] As described above in connection with 12th and 13th embodiments of the present invention, one can prepare a modified Semaphorin Z protein in which the neurite-outgrowth inhibition activity on CNS-neuron has been abolished. When administered into a living body, such modified protein may bind to receptors for Semaphorin Z or to Semaphorin Z itself, resulting in an inhibition of the Semaphorin Z activity and a promotion of the regeneration of CNS-neuron.

[0102] Such modified protein of Semaphorin Z is formulated with a stabilizer, buffer, and diluent, and administered to a patient for therapy. Such formulation may be administered by any one of various routes, and it is preferred to topically administer to the focal site. Since regeneration of neuron usually takes several days to several months, the formulation is administered once or more in order to continuously inhibit the Semaphorin Z activity throughout the period. When administered more than once, it is desirable to administer it every day or repeatedly at appropriate intervals. When administered to CNS by injection, for example, into spinal cord, several hundreds μ g to 2 g, preferably less than several tens mg, are used per administration. To reduce the administration frequency, it may be administered using a sustained-release formulation or gradually administered over a long period by means of, for example, an osmotic pump. Alternatively, it may be administered by grafting into a living body a cell expressing such modified Semaphorin Z protein.

3) Polypeptide derived from Semaphorin Z

[0103] The peptide of the 19th or 20th embodiment of the present invention may suppress the inhibition activity of Semaphorin Z on neurite outgrowth of CNS-neuron by binding to receptors for Semaphorin Z, resulting in a promotion of regeneration of CNS-neuron. As described above in connection with the 20th embodiment of the present invention, polypeptides having such effect include, for example, a polypeptide characterized in that it contains the aspartic acid at position 203 of human Semaphorin Z shown in SEQ ID NO: 6 or an amino acid residue corresponding to said aspartic acid. The suppression may be any one of competitive, noncompetitive, uncompetitive, and allosteric inhibitions.

[0104] As for the methods of formulating or administering such polypeptides, and their doses, see the above section "2) Modified protein of Semaphorin Z".

4) Antibody against Semaphorin Z

[0105] A neutralizing antibody which neutralizes the activity of Semaphorin Z may suppress, when administered into a living body, the activity of Semaphorin Z, and promote the regeneration of CNS-neuron.

[0106] The methods of formulating or administering such neutralizing antibody and their doses may be the same as described in the above section "2) Modified protein of Semaphorin Z". Alternatively, a method in which cells producing a monoclonal antibody are grafted directly into CNS may also be used.

[0107] The above-described screening method of the 24th embodiment of the present invention can be established only after the discovery of Semaphorin Z, a representative protein of the present invention which inhibits neurite outgrowth of CNS-neuron. Once Semaphorin Z has been found, one can easily carry out the screening by using the method as described above. By carrying out such screening, one can easily select Semaphorin Z inhibitor of the 25th or 26th embodiment of the present invention which inhibits the neurite-outgrowth inhibition activity on CNS-neuron exerted by Semaphorin Z. Then, such inhibitor, or an antisense DNA or RNA, or its chemically modified variant, as described above which controls the expression of Semaphorin Z is used as a curative ingredient to formulate a CNS-

neuron regeneration promoter of the 27th embodiment of the present invention. Therefore, these are all achieved concomitantly with the discovery of Semaphorin Z, and are all included within the scope of the present invention.

[0108] The 28th embodiment of the present invention is a neurite-outgrowth inhibitor for PNS-neuron characterized in that it contains at least one of the proteins of the 3rd, 5th, 8th and 11th embodiments of the present invention. Although the proteins of these embodiments inhibit the neurite outgrowth of CNS-neuron, they are also expected to inhibit the neurite outgrowth of PNS-neuron, since PNS-neuron also probably expresses a receptor for Semaphorin Z, and receptors for other Semaphorins also probably react with Semaphorin Z. Accordingly, they may serve as a therapeutic agent for pain or an immune disease such as atopic dermatitis, by virtue of their inhibition activity on neurite outgrowth of PNS-neuron.

[0109] As for the methods of formulating or administering such proteins, and their dose, see the above section "2) Modified protein of Semaphorin Z".

[0110] The 29th embodiment of the present invention is a transgenic animal in which the DNA of the 1st, 4th, 6th, 7th, 9th, 10th or 12th embodiment of the present invention has been artificially inserted into its chromosome, or has been knocked out.

[0111] As apparent from the following references, one skilled in the art can quite easily produce a transgenic animal which has the gene of the 1st, 4th, 6th, 7th, 9th, 10th or 12th embodiment of the present invention inserted into its chromosome, on the basis of the gene information on Semaphorin Z of the present invention (*Manipulation of Mouse Embryo*, B. Hogan *et al.* ed., 1986, Cold Spring Harbor Laboratory; Shinichi Aizawa, *Gene Targeting*, 1995, Yodosha, etc.). Accordingly, the transgenic animal thus produced is naturally included within the scope of the present invention.

The transgenic animal thus produced is very useful as an animal model for developing pharmaceuticals or an animal used for screening of pharmaceuticals. Furthermore, a so-called knockout animal in which the gene of the 1st, 6th or 7th embodiment of the present invention has been deleted at the chromosomal level is characterized in that it does not contain such gene. As described in literatures, or as apparent from the common knowledge in the art, such knockout animals cannot be produced without the gene information on Semaphorin Z of the present invention. It goes without saying, therefore, that such knockout animals are included within the scope of the present invention.

[0112] While Semaphorin Z plays an important role in inhibiting the neurite outgrowth of CNS-neuron *in vivo* as described above, it has been also suggested that Semaphorin gene may have other unknown functions such as immunosuppression (*Cell*, 75, 1389-1399 (1993)). Accordingly, it is quite important to investigate the expression of Semaphorin Z gene or the distribution and function of Semaphorin Z protein for studying this technical field or for diagnosing a patient, for example, with a neural disease. The present invention can provide a gene probe, an antibody, a recombinant protein, a transgenic animal and the like which are useful for such purposes.

BRIEF DESCRIPTION OF DRAWINGS

[0113]

Fig. 1 shows the result of Northern analysis, indicating distribution of Semaphorin Z expression in adult rat tissues.

RNAs were extracted from various tissues of adult rat, separated by an agarose gel electrophoresis, blotted onto a filter, and hybridized with a ^{32}P -labeled probe. The upper panel shows the autoradiogram, and the lower panel shows the ethidium bromide staining of the gel after electrophoresis. The positions corresponding to 28S and 18S rRNAs are indicated at the left margin, and the position corresponding to Semaphorin Z mRNA is indicated at the right margin. 15 μg of RNA was loaded in each lane.

Fig. 2 shows the result of Northern analysis, indicating distribution of Semaphorin Z expression in central nervous tissues.

RNAs were extracted from nine sections of central nervous tissue, separated by an agarose gel electrophoresis, blotted onto a filter, and hybridized with a ^{32}P -labeled probe. The upper panel shows the autoradiogram, and the lower panel shows the ethidium bromide staining of the gel after electrophoresis. The positions corresponding to 28S and 18S rRNAs are indicated at the left margin, and the position corresponding to Semaphorin Z mRNA is indicated at the right margin. 15 μg of RNA was loaded in each lane.

Fig. 3 shows the result of Northern analysis, indicating the change in the amounts of Semaphorin Z expression from embryo to adult.

RNAs were extracted from rat tissues at various ages, separated by an agarose gel electrophoresis, blotted onto a filter, and hybridized with a ^{32}P -labeled probe. The upper panel shows the autoradiogram, and the lower panel shows the ethidium bromide staining of the gel after electrophoresis. RNAs were prepared from the whole embryo at embryonic-day 12 (E12), from the head and the body in the case of embryo at E15, E18 and neonate, and from the whole brain in the adult. The positions corresponding to 28S and 18S rRNAs are indicated at the left margin, and the position corresponding to Semaphorin Z mRNA is indicated at the right margin. 15 μg RNA was loaded in each lane.

Fig. 4 shows the result of SDS-PAGE, indicating the expression of Semaphorin Z extracellular domain (rSZexII) in *Escherichia coli*.

The left panel shows the induced expression of the extracellular domain (rSZexII) in *E. coli* BL21(DE3)pLysS transformed with a Semaphorin Z partial peptide expression plasmid (pRSZexII). This *E. coli* was cultured, and when turbidity (O.D. 600) of the culture reached 0.4-0.6, IPTG was added at a final concentration of 1 mM to induce the expression. The numerals at the top of the panel indicate the time after the IPTG addition. At the indicated times, the culture was sampled. The cells collected by centrifugation were suspended in a SDS-PAGE sample buffer, and after heat denaturation, separated by SDS-PAGE. The expression of rSZexII (arrow) was observed one hour after the induction, and the amount of expression was increased thereafter. The right panel shows the result of SDS-PAGE of rSZexII purified on a nickel affinity column. Lane M indicates the molecular weight markers, and the numerals at the left margin of the figure each indicate the molecular weight (kD: kiloDalton) of the markers.

Fig. 5 shows the result of SDS-PAGE, indicating the expression of the Semaphorin Z cytoplasmic domain (rSZinc) in *E. coli*.

The left panel shows the induced expression of Semaphorin Z cytoplasmic domain (rSZinc) in *E. coli* BL21(DE3)pLysS transformed with a Semaphorin Z partial peptide expression plasmid (pRSZinc). This *E. coli* was cultured, and when turbidity (O.D. 600) of the culture reached 0.4-0.6, IPTG was added at a final concentration of 1 mM to induce the expression. The numerals at the top of the panel indicate the time after the IPTG addition. At the indicated times, the culture was sampled. The cells collected by centrifugation were suspended in a SDS-PAGE sample buffer, and after heat denaturation, separated by SDS-PAGE. The expression of rSZinc (arrow) was appeared 4 hours after the induction, and the amount of expression was increased after 12 hours. The right panel shows the result of SDS-PAGE of rSZinc purified on a nickel affinity column. Lane M indicates the molecular weight markers, and the numerals at the left margin of the figure each indicate the molecular weight (kD: kiloDalton) of the markers.

Fig. 6 shows the result of Western blotting of Semaphorin Z protein expressed in COS cells.

The left panel: COS cells were transfected with (A) antisense-Semaphorin Z gene expression plasmid pUCS-R α SZ(-) or (S) Semaphorin Z expression plasmid pUCSR α SZ. After two days, the membrane fraction and the cytoplasmic fraction were separated, subjected to SDS-PAGE, and then to Western blotting using an anti-Semaphorin Z antibody. (C) indicates a mock transfection. The position corresponding to the Semaphorin Z protein band is indicated at the left margin of the figure. The right panel: the membrane fraction prepared above was treated (Lane (+)) with a glycosidase, N-glycosidase-F, and then analyzed by Western blotting as in the case of the left panel. Lane (-) indicates the result of the same procedure with the exception that the enzyme was not added. The position of Semaphorin Z band is indicated at the right margin of the figure. MW indicates molecular weight makers.

Fig. 7 shows the growth-cone collapse activity of a cell extract prepared from Semaphorin Z-expressing cells.

The extract was prepared from COS 7 cells into which a Semaphorin Z expression plasmid (pAx1CASemaZ-L) has been introduced (+SemaZ). The extract was then added to chicken embryo dorsal root ganglion neuron cultured in the presence of NGF or NT-3, and the ratio (%) of the neurite having collapsed growth cone was determined. As a control, an extract prepared from cells into which a plasmid expressing an antisense-Semaphorin Z gene (pAx1CASemaZ-R) has been introduced was used. The value indicated in the figure is the average of the values obtained from 8 ganglions. Standard deviations are shown in the figure.

Fig. 8 shows the result of electrophoresis, indicating the expression of antisense-Semaphorin mRNA in cells infected with an antisense-adenovirus.

COS 7 cells were infected with an adenovirus expressing antisense-Semaphorin Z gene (antisense-adenovirus: Ax1CASemaZ-R) or an adenovirus having no Semaphorin Z gene (control-adenovirus: Ax1CAwt), and after two days, the total RNA was prepared. Five μ g of the total RNA was electrophoresed on 1% agarose-formaldehyde gel, blotted onto a membrane filter, hybridized with a sense (left panel) or antisense (right panel) cRNA probe labeled with 32 P, and subjected to autoradiography (the upper panels: autoradiogram). Lane 1 and Lane 2 in each figures respectively indicate the results with RNA prepared from the cells infected with the control-adenovirus or antisense-adenovirus. Antisense-Semaphorin Z mRNA was detected using the sense probe only in the cells infected with the antisense-adenovirus (arrow in the left panel: anti-sense semaZ). The lower panels in each figures indicate the ethidium bromide staining of the electrophoresed gels. The positions of 28S and 18S ribosomal RNAs are indicated at the left margin of the figure.

Fig. 9 shows the result of Western blotting, indicating the expression inhibition of Semaphorin Z protein by an antisense-Semaphorin Z gene.

Semaphorin Z expression plasmid (SemaZ expression plasmid, pAX1CASemaZ-L), an antisense-Semaphorin Z expression plasmid (antisense plasmid, pAxCASemaZ-R), an adenovirus having no Semaphorin Z gene (control-adenovirus, AX1CAwt), and an adenovirus expressing an antisense-Semaphorin Z gene (antisense-adenovirus, Ax1CASemaZ-R) were introduced into COS cells in the indicated combinations. After a certain period, the cells were harvested, and the membrane fraction was prepared. The membrane fraction was separated by SDS-PAGE,

and then subjected to Western blotting using an anti-Semaphorin Z antibody. The time when Semaphorin Z expression plasmid is transfected was defined as 0 hour, and cells were harvested after 12 and 24 hours. Infection with adenovirus was performed 24 hours before the transfection with the plasmid. The position of Semaphorin Z band is indicated at the left margin of the figure, and also indicated by a triangle at the side of each lanes.

Fig. 10 shows the result of Northern analysis, indicating distribution of Semaphorin III expression in various tissues *in vivo*.

To determine the distribution of expressed Semaphorin III, the total RNAs were extracted from various tissues in adult rat, electrophoresed on 1% agarose-formaldehyde gel, blotted onto a filter, and hybridized with a mouse Semaphorin III DNA probe labeled with ³²P. The lanes each contained 15 µg RNA. The upper panel indicates the result of autoradiography. The positions of 18S and 28S ribosomal RNAs are indicated at the left margin of the figure. The lower panel indicates the ethidium bromide staining of the gel. The upper band and the lower band in the panel respectively correspond to 28S and 18S ribosomal RNAs.

EXAMPLES

[0114] Fundamental procedures for experiments are described in detail in many publications such as *Molecular Cloning, 2nd Ed.* (Maniatis *et al.* ed., Cold Spring Harbor Laboratory Press, 1989), *Current Protocols in Molecular Biology* (Ausubel *et al.* ed., John Wiley & Sons, 1987), and *Saibo-Kogaku-Jikken Protocols* (edited by Department of Oncology, The Institute of Medical Science, The University of Tokyo, Shujunsha, 1991). The present invention is not intended to be limited by the following examples, and the examples may be of course modified as usual.

Example 1: Cloning of rat Semaphorin Z gene

(1) Search through database for a novel Semaphorin gene

[0115] Using the dbEST database of the National Center for Biotechnology Research (Bethesda, MD, US), search was performed for a sequence which encodes an amino acid sequence relatively well conserved in known Semaphorin genes and which is found in only cDNAs from postnatal brain but not in cDNAs from fetus. As a result, the nucleotide sequence of File No. T08532 proved to have a sequence (Gln-Asp-Pro-Tyr-Cys-Gly-Trp-Ala) which is similar to the sequence of 8 amino acids common to known Semaphorin genes (Gln (or Arg)-Asp-Pro-Tyr (or His)-Cys-Ala (or Gly)-Trp-Asp). However, the sequence information of T08532 consisting of 176 bases is so short compared with the cDNAs for known Semaphorin genes, and only about 10% of the total nucleotides could be translated to a sequence common to those in known Semaphorins. In addition the reading frame could not be determined because the sequence of T08532 is not the one finally determined. It was, therefore, impossible to conclude that the sequence is part of a novel Semaphorin gene. Thus, the present inventors adopted the following strategy. Firstly, we confirmed that a gene containing the above sequence was expressed in adult brain, which is required for the aim of the present invention. The full length cDNA containing the above sequence was then cloned, and the structure of the gene was determined to judge whether or not it corresponds to a novel Semaphorin.

(2) Confirmation of the expression of the gene containing the sequence of T08532 in the brain

[0116] To confirm that the gene is expressed in adult human CNS, two DNA primers (5'-AAGATGCAGGAGCCGTCG-3' (SEQ ID NO: 8), and 5'-CAGCGGCTGCTGAGCTTG-3' (SEQ ID NO: 9)) were synthesized on the basis of the nucleotide sequences at each end of T08532, and used in a PCR reaction under usual conditions together with cDNAs prepared from a human hippocampal cDNA library (Stratagene) as a template. As a result, about 170 bp fragment approximately equal to total-length of T08532 was amplified. To confirm that the fragment has the same base sequence as that of T08532, the DNA was then cloned into pCRII (Invitrogen) according to the protocol supplied by Invitrogen, and the total nucleotide sequence was determined. More than 95% of the sequence thus obtained (SEQ ID NO: 7) coincided with that of T08532, confirming that a gene containing the sequence of T08532 is expressed in the adult human brain.

(3) Isolation of rat Semaphorin Z gene

[0117] Then, the inventors have decided to clone the full-length of the gene to determine whether or not the gene corresponds to a novel Semaphorin. Since it is expected that in the subsequent research, a rat gene preparation may be more easily accessible than a human gene, the rat gene was firstly cloned. Specific procedures for such cloning are as follows.

[0118] Firstly, the 176 bp cDNA fragment (SEQ ID NO: 7) obtained in the above section (2) was used as a probe to

screen a cDNA library in the following manner. The cDNA library was prepared by the conventional method described in the above-mentioned laboratory manuals using mRNA prepared from rat brain by the conventional method and Lambda Zap II (λ ZapII) cDNA Library Preparation Kit (Stratagene) to obtain about 150 thousand plaques. These plaques were transferred onto a nylon membrane (Nippon Pall). The DNAs were denatured, neutralized, fixed with ultraviolet rays of 0.6 J/cm², and then used in a hybridization. The hybridization was conducted at 42°C for 48 hours by adding the nylon membrane and the 176 bp DNA fragment labeled with ³²P (prepared using Megaprime DNA Labeling System (Amersham)) as a probe to a hybridization buffer (45% (v/v) formamide, 5x SSPE (1x SSPE consists of 0.15 M sodium chloride, 10 mM sodium dihydrogenphosphate, and 1 mM disodium ethylenediaminetetraacetate, adjusted to pH 7.0), 2x Denhardt's solution (Wako Pure Chemical Industries), 0.5% (w/v) sodium dodecyl sulfate (SDS), 20 µg/ml salmon sperm DNA (Wako Pure Chemical Industries)). After the reaction, the nylon membrane was washed 2-3 times in 2x SSPE, 0.5% (w/v) SDS at room temperature for 10 min, and further washed 2-3 times in 2x SSPE, 0.5% (w/v) SDS at 42°C for 10 min. The filters thus prepared were analyzed using BAS 2000 Bio Image Analyzer (Fuji Film), and 4 positive signals were obtained. Plaques corresponding to the positive signals were excised from the agarose plate, placed in 500 µl of SM buffer (100 mM sodium chloride, 15 mM magnesium sulfate, 50 mM Tris (pH 7.5), 0.01% gelatin) supplemented with 20 µl of chloroform, and left overnight at 4°C to elute the phages. The recombinant lambda phages thus obtained were subjected to a secondary screening according to the procedures as described above, and single plaques were isolated. The phages thus obtained were treated in the following manner for *in vivo* excision of a phagemid containing the cDNA insert, according to the protocols supplied by Stratagene. Agarose gels containing the 4 single plaques obtained in the secondary screening were each placed in 500 µl of SM buffer, supplemented with 20 µl of chloroform, and then allowed to stand overnight at 4°C. Two hundred fifty µl of the phage solution obtained, 200 µl of *E. coli* XL-1 Blue MRF' suspended in 10 mM magnesium chloride at OD₆₀₀=1.0, and 1 µl of ExAssist helper phage (>1x10⁶ pfu/ml) were mixed, and incubated at 37°C for 15 min. Then, 3 ml of LB medium (prepared by mixing 0.5% (w/v) sodium chloride, 1% (w/v) Bactotrypton (Difco), and 0.5% (w/v) yeast extract (Difco) and the mixture was then adjusting to pH 7.0 using 5 M sodium hydroxide) was added, and the mixture was shaken at 37°C for 2-3 hours. The cells were removed by centrifuging at 2000xg for 15 min, and the supernatant was shaken at 37°C for 2-3 hours. The supernatant was then centrifuged again at 2000xg for 15 min, and the supernatant was treated at 70°C for 15 min. The phagemid containing the cDNA insert. An aliquot (10-100 µl) of the phagemid stock solution was mixed with 200 µl of *E. coli* SOLR (OD₆₀₀=1.0), incubated at 37°C for 15 min, and 10-50 µl of the mixture was then plated onto an ampicillin plate, incubated overnight at 37°C to obtain *E. coli* strain containing a double stranded phagemid into which the gene fragment of interest has been inserted.

(4) DNA sequencing

[0119] The nucleotide sequence of the cDNA clone obtained was analyzed on Model 377 DNA Sequencer (Perkin-Elmer) to determine the total nucleotide sequence. The reaction was carried out using PRISM Dye termination kit (Perkin-Elmer). The DNA nucleotide sequence thus determined (3692 bases), the putative open reading frame (2664 bases), and the amino acid sequence (887 amino acids) are shown in SEQ ID NOs: 1, 2, and 3, respectively. [0120] By comparing the sequence of the gene with known sequences in database, the gene has proved to be a novel gene. Furthermore, it was definitely confirmed that it is a novel protein belonging to the Semaphorin family, since the region from position 49 to position 580 of the amino acid sequence has a homology to the so-called Semaphorin domain sequence, and 12 cysteines among 13 cysteines highly found among Semaphorin genes are conserved also in the novel sequence. Thus, the novel protein was designated Semaphorin Z.

Example 2: Cloning of human Semaphorin Z gene

[0121] Two primers (5'-TACTTCAATGTACTGCAGGCT-3' (SEQ ID NO: 10) and 5'-AAGATGCAGGAGCCATOGGGG-3' (SEQ ID NO: 11)) were synthesized on the basis of the nucleotide sequence of rat Semaphorin Z obtained in Example 1, and used in a PCR reaction together with cDNAs prepared from a human frontal lobe cortex cDNA library (Stratagene) as a template to amplify a cDNA fragment corresponding to human Semaphorin Z. The amplified fragment was cloned into pCRII (Invitrogen), and the nucleotide sequence was determined as described in Example 1. To exclude any errors during the PCR reaction, the nucleotide sequences of 4 independent clones were compared, and the correct sequence was determined. [0122] Apart from the above, the sequence of rat Semaphorin Z was compared with sequences in EST database (dbEST) using a homology analysis program, blastn, in order to find an EST clone encoding the DNA sequence of human Semaphorin Z. As a result, z45909 has proved to have a sequence highly similar to that of rat Semaphorin Z. Accordingly, an EST clone containing this sequence (ID#184382) was purchased from Genome Systems Inc. (US), and the total base sequence was determined by the method described in Example 1. [0123] For a region of which nucleotide sequence could not be determined by such two methods, a human forebrain

cDNA library was repeatedly screened using a rat Semaphorin gene fragment corresponding to such undetermined human region as a probe. In this manner, the nucleotide sequence encoding the full-length human Semaphorin Z was finally determined. The DNA nucleotide sequence thus determined (3524 bases), the putative open reading frame (2667 bases), and the amino acid sequence (888 amino acids) are shown in SEQ ID NOs: 4, 5, and 6, respectively. The amino acid sequence shown in SEQ ID NO: 6 has proved to represent human Semaphorin Z, since it showed 89% identity with the amino acid sequence of rat Semaphorin Z shown in SEQ ID NO: 3.

Example 3: Tissue-specific gene expression of Semaphorin Z confirmed by Northern analysis

10 (1) Preparation of RNA

[0124] Various tissues were excised from rat, and RNAs were prepared therefrom by AGPC method (Takashi Tuji and Toshikazu Nakamura, *Jikken-Igaku*, vol. 9, 1991, pp. 1937-1940; M. F. Ausubel *et al.* ed., *Current Protocols in Molecular Biology*, 1989, pp. 4.2.4-4.2.8, Greene Pub. Associates & Wiley-Interscience). Briefly, 10 ml of a denaturing solution (4M guanidine thiocyanate, 25 mM sodium citrate (pH 7.0), 0.5% sarkosyl, 0.1 M 2-mercaptoethanol) was added to each 1 g of excised tissue, and quickly homogenized using a Polytron homogenizer. To the homogenate, 0.1 volume of 2 M sodium acetate (pH 4.0), 1 volume of water-saturated phenol, and 0.2 volumes of chloroform-isoamyl alcohol (49:1) were added, and the mixture was vigorously stirred. After centrifugation, the aqueous layer was isolated, an equal volume of isopropyl alcohol was added thereto, and the mixture was allowed to stand at -20°C for 1 hour. The precipitate was recovered by centrifugation, and dissolved again in 2-3 ml of the denaturing solution per 1 g tissue. An equal volume of isopropyl alcohol was added, and the mixture was allowed to stand at -20°C for 1 hour, and then RNA was centrifuged. The precipitate was washed with 75% ethyl alcohol, briefly dried, and then dissolved in an appropriate amount of water.

25 (2) Electrophoresis and Northern blotting of RNA

[0125] Electrophoresis and Northern blotting of RNA were performed according to *Molecular Cloning 2nd Ed.* (Maniatis *et al.* ed., Cold Spring Harbor Laboratory Press (1989)). Briefly, RNAs prepared from various tissues were electrophoresed on 1% agarose gel containing formaldehyde. The gel was shaken in 50 mM NaOH for 20 min, and then in 10x SSPE for 40 min. The RNAs were then blotted onto a nylon membrane (Biodyne B, Nippon Pall) by means of capillary transfer, and fixed using an UV cross-linker (Stratagene) (0.6J/cm²).

(3) Hybridization

[0126] Using two primers (5'-CAGGAACACGAACCACAC-3' (SEQ ID NO: 12) and 5'-GTATGCAAGAATGATGTG-3' (SEQ ID NO: 13)), PCR reaction was carried out with rat Semaphorin Z cDNA as template to obtain a fragment of 775 bp. This DNA fragment was labeled with ³²P as described in Example 1, and used as a probe. Hybridization was carried out at 42°C for 16-24 hours by incubating the nylon membrane on which RNAs have been blotted with the DNA probe in a hybridization buffer same as that described in Example 1. After the reaction, the nylon membrane was washed 2-3 times in 2x SSPE, 0.5% (w/v) SDS for 10 min at room temperature, and further washed 2-3 times in 2x SSPE, 0.5% SDS (w/v) at 65°C for 20 min. The filter thus prepared was subjected to autoradiography for analysis.

(4) Results

[0127] As shown in Fig. 1, mRNA of Semaphorin Z was highly expressed in adult CNS (cerebrum, cerebellum), whereas it was scarcely expressed in peripheral tissues except for spleen. Furthermore, as shown in Fig. 2, Semaphorin Z of the present invention was expressed throughout the entire tissues of CNS, although particularly high expression was observed in cerebellum, hippocampus, and corpus striatum. In addition, as shown in Fig. 3, the expression of Semaphorin Z mRNA was very weak in embryos, and in particular the expression was hardly observed in an embryonic-day 12 embryo (E12 embryo), and a newborn rat.

[0128] As mentioned above, Semaphorin Z of the present invention has the characteristics that 1) it is highly expressed in adult CNS in general and 2) it is poorly expressed in embryos or peripheral tissues in the adult where the neurite outgrowth is not inhibited. It was thus demonstrated that Semaphorin Z of the present invention exhibits an expression distribution which may be considered as typical of a "CNS-neuron regeneration inhibitor".

55 Example 4: Expression of Semaphorin Z by *E. coli*

[0129] The cytoplasmic domain and the extracellular domain of Semaphorin Z were separately expressed in the fol-

lowing manner.

[0130] Firstly, Semaphorin Z cDNA (SEQ ID NO: 1) was cleaved with restriction enzymes *AatII* and *EcoRI*, and electrophoresed on an agarose gel to prepare a fragment of 1.9 kb. The 1.9 kb fragment was ligated to an expression plasmid pRSETc (Invitrogen) cleaved at *XhoI-EcoRI* site together with an adapter DNA (5' TCGAGATCTGCAGCTGACGT 3'/5' CAGCTGCAGATC 3') to obtain a plasmid named pRSZinc for expression of the cytoplasmic domain.

[0131] Next, Semaphorin Z cDNA (SEQ ID NO: 1) was cleaved with *BstBI* and *XhoI*, and the 0.86 kbp fragment was separated and isolated by agarose gel electrophoresis. The fragment was ligated to pRSETc cleaved at *XhoI-BstBI* site using two adapters (5'

TCGAGCTGTGACTGGTGTGGTGACGGTCCCCG 3'/5'

GGCCGCCAAGGCTCACCACACCAAGTCACAGC 3' and 5'

CCTGATAATAGTT 3'/5' CGAACTATTATCAGGACGT 3') to obtain a plasmid, named rSZexII, for expression of the extracellular domain.

[0132] Using the plasmid pRSZinc or pRSZexII thus obtained, *E. coli*. BL21(DE3)pLysS (Stratagene) was transformed, and cultured overnight on a LB plate containing 50 µg/ml ampicillin to obtain a transformant. By analyzing the nucleotide sequence, it was confirmed that the transformant carry a plasmid having the desired structure. The transformant was cultured with shaking in LB broth containing 50 µg/ml ampicillin, and when OD₆₀₀ reached 0.5, IPTG was added at a final concentration of 1 mM, and further cultured for 12 hours. Subsequently, the culture medium was centrifuged at 5000g for 15 min to harvest the cells. The whole proteins of the harvested cells were analyzed by SDS-PAGE, and it was confirmed on the basis of the molecular weights that the desired proteins, that is, rSZinc (the cytoplasmic domain of Semaphorin Z) and rSZexII (the extracellular domain of Semaphorin Z) have been produced. The results are shown in Figs. 4 and 5.

Example 5: Purification of Semaphorin Z

[0133] The above-described rSZinc and rSZexII expressed in *E. coli* were affinity-purified using the affinity between the histidine tag located at the amino terminal of these proteins and a nickel-NTA resin. The procedure is described in detail in the protocols of Qiagen attached to the nickel-NTA resin (QIAexpressionist). Briefly, 5 ml of A solution (6M guanidine-HCl, 0.1 M sodium phosphate, 0.01 M Tris-HCl pH=8.0) was added to each 1 g of *E. coli* cells expressing rSZinc or rSZexII obtained by the method described in Example 4. The cells were suspended well in the solution, and stirred at room temperature for more than 1 hour to be solubilized. The solution was then mixed with a nickel-NTA resin pre-equilibrated with A solution, gently stirred at room temperature for more than 2 hours to allow the binding of the desired protein to the resin, and then the resin was packed into a column. The column was washed with 10 volumes of A solution, then with 5 volumes of B solution (8M urea, 0.1 M sodium phosphate, 0.01 M Tris-HCl pH=8.0), and further with 5 volumes of C solution (8M urea, 0.1 M sodium phosphate, 0.01 M Tris-HCl pH=6.3). The bound proteins were then eluted with 2 volumes of D solution (8 M urea, 0.1 M sodium phosphate, 0.01 M Tris-HCl pH=5.9), and further eluted with E solution (8M urea, 0.1 M sodium phosphate, 0.01 M Tris-HCl pH=4.5). During the elution, the eluate was collected in one column volume fractions, and subjected to SDS-PAGE to check the proteins eluted. The desired fractions were then concentrated, and stored at -20°C until use.

[0134] The N-terminal amino acid sequence of the purified rSZinc and rSZexII thus obtained was determined to confirm that they were the desired proteins. The results of SDS-PAGE of these purified rSZinc and rSZexII are shown in Figs. 4 and 5.

Example 6: Production of anti-Semaphorin Z antibody

[0135] The purified rSZinc or rSZexII obtained in Example 5 was separated by SDS-PAGE (6% polyacrylamide gel), stained with CBB, and the desired band was excised. The excised gel block was cut into small pieces, and its aliquot corresponding to 0.4 mg protein was mixed with Freund's complete adjuvant. Using the mixture, a rabbit was then subcutaneously immunized. Subsequently, the rabbit was further subcutaneously immunized 3 times at intervals of 2 weeks with 0.2 mg of the protein mixed with Freund's incomplete adjuvant. One week after the last immunization, whole blood was collected from the rabbit. Purification was carried out by the conventional method using a protein A column, an rSZinc or rSZexII affinity column to obtain a purified polyclonal antibody.

[0136] Since the antibody has recognized Semaphorin Z of the present invention in Western blotting described below in Example 7, and the antibody pre-absorbed to the antigen, i.e., rSZinc or rSZexII, has failed to recognize Semaphorin Z, the antibody has proved to react specifically with Semaphorin Z.

Example 7: Expression of Semaphorin Z by mammalian cells

[0137] Semaphorin Z cDNA (SEQ ID NO: 1) was inserted into the *EcoRI* site of an expression vector for mammalian

cell, pUCSR α , to obtain an expression plasmid pUCSR α SZ. COS 7 cells were transfected with pUCSR α SZ using DEAE-dextran method (F. M. Ausubel *et al.* ed, *Current Protocols in Molecular Biology*, John Wiley & Sons (1987)). After 48 hours, the cells were harvested using a cell scraper. The cells harvested were homogenized in the presence of A solution containing protease inhibitors (Hanks' physiological saline containing 10 mM HEPES pH 7.4, 1 mM EDTA, 50 μ M leupeptin, 2 μ M pepstatin, 0.5 mM PMSF, and 7.8 mTIU/ml aprotinin), and separated into the precipitate and the supernatant by high-speed centrifugation at 12000g for 10 min. Since the supernatant still contained a considerable amount of the membrane fraction, it was further ultracentrifuged at 100000g for 30 min, and the supernatant was recovered as a cytoplasmic fraction. The cytoplasmic fraction obtained was stored at -80°C until use. The precipitate from the high-speed centrifugation were washed twice with A solution, suspended in 2 volumes of 2.25 M sucrose/PBS, and overlaid onto 2.25 M sucrose/PBS. After 0.8 M sucrose/PBS was further overlaid, it was centrifuged at 12000g for 20 min. The membrane fraction was recovered from the lower interface, further washed twice, and stored at -80°C until use.

[0138] The cytoplasmic fraction and the membrane fraction obtained were subjected to SDS-PAGE (10%-20% gradient gel), and then to Western blotting by the method described below in Example 11 to confirm that Semaphorin Z of the present invention was expressed, and that it existed only in the membrane fraction. The result was shown in Fig. 6. As apparent from Fig. 6, Semaphorin Z expressed in the present Example had an apparent molecular weight of 110-150 kDa. When treated with N-glycosidase, the molecular weight of Semaphorin Z became about 110-130 kDa (Fig. 6), which is close to 93 kDa, the expected molecular weight calculated from the amino acid sequence.

[0139] The results described above demonstrated that Semaphorin Z of the present invention is a glycoprotein localized in the membrane. In the present Example, samples prepared in the same manner as described above from COS 7 cells which were mock-transfected, or transfected with antisense-Semaphorin Z expression plasmid pUCSR α SZ (-), were used as controls.

Example 8: Measurement of the growth-cone collapse activity of Semaphorin Z

[0140] Semaphorin Z cDNA (SEQ ID NO: 1) was inserted into the *Eco*RI site of an expression vector for mammalian cells, pUCSR α , in the sense or antisense direction to obtain expression plasmids pUCSR α SZ(+) and pUCSR α SZ(-). COS 7 cells were transfected with these expression plasmids by the DEAE-dextran method described in Example 7, and after 48 hours, harvested using a cell scraper. The cells harvested were homogenized (20 strokes) using a Dounce homogenizer (tight type) in the presence of protease inhibitors as described in Example 7. The cell homogenate was obtained by centrifuging the mixture at 12000g for 5 min to remove the precipitate. The protein concentration of this homogenate was measured by the BCA method (Pierce).

[0141] The dorsal root ganglion (DRG) was dissected from chicken embryonic-day 8 embryo (E8 embryo), incubated at 37°C for 13 hours in F12 medium/10% FCS containing 20 ng/ml NGF or NT-3 in the presence of 5% CO₂ in a chamber slide coated with poly-L-lysine-laminin, and subjected to a measurement of the growth-cone collapse activity. The method of measuring the growth-cone collapse activity is described in detail in *Neuron*, 2, 11-20 (1990), *Neuron*, 2, 21-29 (1990), *Neuron*, 2, 31-37 (1990). Briefly, the measurement was carried out according to the following procedures: Firstly, the above cell homogenate, 1/4 volumes relative to the medium, was added to the chamber containing the cultured dorsal root ganglion, incubated at 37°C for 1 hour, and then fixed by adding 1% glutaraldehyde/PBS for 15 min. After washing once with PBS, a specimen was prepared using a mounting agent (MountQuick, Daido Sangyo). After confirming that the mounting agent has hardened, the number of collapsed growth cones were counted under a microscope. For each sample, four chambers each containing 2 dorsal root ganglions were incubated, and the average and deviation were calculated. As described in *Neuron*, 2, 21-29 (1990), evaluation of collapse was done on about 50 neurites having the longest length for each dorsal root ganglion.

[0142] As shown in Fig. 7, the extract of COS cell expressing Semaphorin Z (semaZ) had significantly higher growth-cone collapse activities on NGF or NT-3 dependent DRG neural growth cone ($p < 0.001$ and $p < 0.01$, respectively).

Example 9: Construction of recombinant adenovirus expressing Semaphorin Z

[0143] The method of preparing adenoviruses are described in detail in *Jikken-Igaku-Zokan* vol. 12, #15 (1994). Briefly, a recombinant adenovirus expressing Semaphorin Z cDNA in the antisense direction was prepared by the following method. The *Eco*RI-*Mlu*I fragment of Semaphorin Z cDNA (SEQ ID NO: 1) was prepared, blunted by DNA polymerase Klenow fragment, and ligated to an adenovirus cassette cosmid pAx1CAwt cleaved with *Swa*I. The construct was *in vitro* packaged, and transfected to *E. coli* DH5 α . Cosmid DNA was prepared from the transformant thus obtained, and it was confirmed from its restriction enzyme cleavage pattern that Semaphorin Z cDNA has been inserted in the antisense direction. This cosmid was designated pAx1CASemaZ-R. In addition, a Semaphorin Z expression cosmid was prepared in the same manner, and designated pAx1CASemaZ-L. The pAx1CASemaZ-R was co-transfected into 293 cells together with wild-type adenovirus type-5 DNA by the calcium phosphate method. The next day the 293

cells were mixed with untreated 293 cells, re-plated on a 96-well plate, and their cytopathic states were observed everyday. The cells began to degenerate after 10 days. After additional 3-5 days, clones corresponding to the wells in which all the cells were lysed were selected for the next infection. Using the selected clones, 293 cells placed in 25 cm² flasks were infected, and incubated until all the cells were lysed. The culture for each cell was separately collected, and its aliquot was used to prepare the DNA in order to confirm that Semaphorin Z cDNA has been inserted in the antisense direction. With a clone having the insert in the correct direction, the infection of 293 cells was repeated twice to amplify the virus. The amplified virus was then purified, and stored at -80°C in 10% glycerol/PBS(-) until use.

Example 10: Expression of antisense-Semaphorin Z mRNA by a recombinant adenovirus

[0144] 2x10⁶ COS 7 cells were cultured sub-confluently, and the medium was removed. To the cells, 0.3 ml of the recombinant adenovirus (moi=10) was added, and the mixture was allowed to stand for 1 hour, and then 4.7 ml of medium was added hereto. After incubating for 2 days, the total RNA was extracted using ISOGEN (Nippon Gene). Ten µg of the RNA was used for Northern blotting in the same manner as described in Example 3, and the filter obtained was hybridized with an RNA probe specifically labeled on the sense- or antisense-strand of Semaphorin cDNA with ³²P. As shown in Fig. 8, a strong signal was observed only when the sense probe was used, confirming that the recombinant adenovirus Ax1CASemaZ-R highly and selectively expresses the antisense-Semaphorin Z mRNA. Detailed for the preparation of the RNA probe used herein can be found in *Molecular Cloning 2nd Ed.* (Cold Spring Harbor Laboratory Press, 1989). Briefly, however, the sense probe was for example, synthesized in the following manner. Firstly, 2 primers (5'-CAGGAACACGAACACAC-3' (SEQ ID NO: 12) and 5'-GTATGCAAGAATGATGTG-3' (SEQ ID NO: 13)) were used in a PCR reaction with rat Semaphorin Z cDNA as a template to obtain a fragment of 775 bp. This DNA fragment was cloned into pCRII (Invitrogen), and its direction of insertion was confirmed. This plasmid was cleaved with *SpeI*, and used as a template for preparing the probe. The labeling reaction was carried out at 37°C for 1 hour in a total volume of 20 µl containing 0.5 µg of the template, 2 µl of 10x buffer, 4 µl of 2.5 mM rATP, rGTP, and rCTP, 2.4 µl of 100 µM rUTP, 5 µl of [³²P] rUTP, 1 µl (20 units) of T7 polymerase, 1 µl of RNase inhibitor, and distilled water. After adding 2 µl of DNase, the reaction was further continued for 15 min. The antisense probe was prepared in the same manner as before with the exceptions that the template was cleaved with *EcoRV* instead of *SpeI*, and that SP6 polymerase was substituted for T7 polymerase.

Example 11: Inhibition of Semaphorin Z expression by a recombinant adenovirus

[0145] 1x10⁶ COS 7 cells were plated on a collagen (type I)-coated cell culture flask having a culture area of 25 cm² (Sumitomo Bakelite), and incubated for about one day in 5 ml of medium (DMEM+10% FCS) at 37°C under 5% CO₂. The medium was then changed to 0.3 ml medium containing 2x10⁸ pfu of a recombinant adenovirus (an antisense-Semaphorin Z or a control virus having no Semaphorin Z gene), and the cells were further incubated for 1 hour, allowing the cells be infected by the adenovirus. During the infection, the flask was shaken at intervals of about 15 min in order to avoid drying of the cells. Then, 4.7 ml of the culture medium was added, further incubated for one day, and 3 µg of the Semaphorin Z expression plasmid (pAx1CASema2-L) was introduced into the cells using Transfectam (Bio Septra Inc.). A DNA solution containing the expression plasmid was prepared according to the attached protocol, and the DNA solution was contacted with the cells for 4 hours. At 12 and 24 hours after the introduction of the expression plasmid, the cells were harvested in the following manner. The cells were detached in the presence of medium using a cell scraper, collected by centrifugation (1000 rpm, 5 min, 4°C), washed with PBS, and then suspended in 100 µl of a lysis buffer (Hanks' physiological saline containing 10 mM HEPES pH 7.4, 1 mM EDTA, 50 µM leupeptin, 2 µM pepstatin, 0.08 TIU/ml aprotinin, and 0.5 mM PMSF). Then, the cells were lysed by freeze-thawing, and separated into a soluble fraction and an insoluble fraction. The insoluble fraction was suspended in a denaturing solution (100 mM Tris-HCl pH 6.8, 2% SDS, 5% 2-mercaptoethanol), denatured and solubilized by heating at 100°C for 10 min. The relative amounts of protein among samples were calculated by measuring the absorbance of the samples at 280 nm, and used in the following Western blot analysis. An aliquot containing a predetermined amount of protein was removed from each sample, mixed with an equal volume of 1x SDS-PAGE sample buffer (0.0625 M Tris-HCl pH6.8, 2% SDS, 5% 2-mercaptoethanol, 10% glycerol), and heated at 100°C for 5 min. These protein samples were fractionated by SDS-PAGE (10% acrylamide), and then electrophoretically transferred (100V, 1 hour, in 25 mM Tris-HCl, 192 mM glycine, and 20% methanol) onto Immobilon filter (Millipore). After shaking for 1 hour in a blocking solution (2% skim milk, 1% BSA) to avoid any non-specific adsorption of antibody, the filter was placed in PBS containing 1/100 volume of the anti-Semaphorin Z antibody obtained in Example 6 as a primary antibody and 0.1% BSA, and allowed to stand overnight at 4°C. The next day the excessive antibody was washed off with PBS containing 0.05% Tween 20 (5 min, 3 times), and then shaken for 1 hour in PBS containing 1/1000 volume of an alkaline phosphatase-labeled anti-rabbit IgG antibody (BIOSORUCE) as a secondary antibody and 0.1% BSA. The filter was then washed as described above, and a developing solution (0.3 mg/ml NBT, 0.15 mg/ml BCIP, 100 mM Tris-HCl pH 9.5, 0.5 mM MgCl₂) was added. When a band of interest was

detected, the solution was replaced with distilled water to stop the developing reaction.

[0146] As shown in Fig. 9, the expression of Semaphorin Z protein was observed 24 hours after the introduction of the expression plasmid for the cells infected with the control-adenovirus, but not for the cells infected with the antisense-adenovirus. Thus, the expression of Semaphorin Z protein was inhibited by the infection of the antisense-adenovirus.

Reference example 1: Identification of the site essential to the Semaphorin activity using Semaphorin III

[0147] PCR was conducted on the basis of the sequence information on Semaphorin III described in *Neuron*, 14, 941-948 (1995), and the structural gene of Semaphorin III was inserted into an expression plasmid pUCSR α . The expression plasmid was then introduced into COS 7 cell by the DEAE-dextran method. After 2 days, the Semaphorin III activity contained in the culture supernatant was determined by a method similar to that described in *Cell*, 75, 217-227 (1993), using the growth-con collapse activity on chicken dorsal root ganglionic neuron as an indicator. As a result, one clone which did not exhibit any activity was found. The nucleotide sequencing of that clone revealed that aspartic acid at position 198 was substituted by glycine. When compared with other known animal Semaphorins, the regions before and after the position 198 were not markedly conserved, although the position corresponding to that aspartic acid was highly conserved among Semaphorins with a few exceptions in which glutamic acid was located at that position. This suggested that the aspartic acid is essential to expression of the activity. The gene was then subjected to a site-directed mutagenesis by a conventional method to replace the glycine with aspartic acid. Since this mutagenesis restored the strong collapse activity, it was confirmed that all the regions in the expression plasmid normally function except for that position. In conclusion, the aspartic acid at position 198 of Semaphorin III appears essential to expression of the Semaphorin function. The amino acid residues corresponding to the aspartic acid are the aspartic acid at position 204 in the amino acid sequence of rat Semaphorin Z shown in SEQ ID NO: 3, and the aspartic acid at position 203 in the amino acid sequence of human Semaphorin Z shown in SEQ ID NO: 6.

Reference example 2: Tissue-specific gene expression of Semaphorin III determined by Northern analysis

[0148] To determine the expression distribution of Semaphorin III gene in mouse tissues, RNAs were prepared from various adult mouse tissues, and subjected to Northern analysis. The procedures for preparation, blotting, and hybridization of RNA were as those described in Example 1. As a probe, the 560 bp *Msp*I fragment of mouse Semaphorin III DNA described in Reference example 1 was used. As a result, it was demonstrated as shown in Fig. 10 that the expression of Semaphorin III in adult is very high in lung which is a peripheral organ, while it is rather low in CNS.

EFFECTS OF THE INVENTION

[0149] The present invention may provide a gene for novel Semaphorin Z inhibiting neurite outgrowth, another Semaphorin gene hybridizing to said gene, DNA or RNA having a sequence complementary to those genes, a protein obtained by expressing Semaphorin Z gene, a partial peptide of Semaphorin Z, a modified protein obtained by expressing a modified gene, and antibodies against them, as well as a screening system for Semaphorin Z inhibitor using Semaphorin Z, a Semaphorin Z inhibitor isolated from said system, and so on. By using such materials or systems, pharmaceutical agents principally having a CNS-neuron regeneration effect, or reagents useful in the medical and biological research on Semaphorin Z are provided.

SEQUENCE LISTING

SEQ ID NO: 1

SEQUENCE LENGTH: 3692 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: No

ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: rat (*Rattus norvegicus*)

STRAIN: Wistar

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: 5' UTR

LOCATION: 1..18

IDENTIFICATION METHOD: E

FEATURE KEY: CDS

LOCATION: 19..2682

IDENTIFICATION METHOD: E

FEATURE KEY: 3'UTR

LOCATION: 2683..3653

IDENTIFICATION METHOD: E

FEATURE KEY: polyA site

LOCATION: 3654..3692

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

GGTCACCTGG TCCTCACCAT GTGGACCCCG CGAGCGCCCC CTCCACGCCC GGCCCTGCTG 60
TTCTCCTGCTG TGTGCTTCT GAGGGTCACC CATGGCCTTT TCCCAGATGA ACCACCTCCA 120
CTCAGTGTGG CTCCCAGGGA CTACCTGAGC CACTACCCCG TGTTCTGTTGG CAGCGGGCCT 180
GGTCGTCTGA CCCCTGCAGA GGGTGCTGAG GACCTCAACA TCCAGAGAGT GCTACGTGTT 240
AACAGGACAC TGTTTCATCGG GGACAGAGAC AACCTGTACC AAGTAGAACT GGAGCCATCC 300
ACATCCACGG AGCTGCGGTA TCAGCGGAAG CTTACCTGGC GCTCCAACCC CAGTGACATC 360
GATGTGTGTC GGATGAAGGG CAAGCAAGAG GGTGAGTGTG GGAACCTTGT CAAGGTGCTC 420
CTGCTTCGTG ACGAATCCAC GCTCTTCGTG TCGGCTCCA ATGCATTCAA TCCCATCTGT 480
GCCAATTACA GTATGGACAC ACTGCAGCTT CTTGGAGACA ACATCAGTGG TATGGCCCGC 540
TGCCCCTACG ACCCAAGCA TGCCAATGTC GCCCTCTTCT CAGATGGGAT GCTCTTCACA 600
GCCACAGTAA CTGACTTCCT AGCCATCGAC GCTGTTATCT ACCGTAGCCT TGGGGACCGG 660
CCCACACTGC GCACAGTAAA GCATGACTCC AAGTGGTTTA AAGAGCCATA CTTTGTGCAT 720
GCGGTGGAGT GGGGAAGCCA CGTCTACTTC TTCTCCGGG AGATCGCCAT GGAGTTTAAC 780
TATCTGGAAA AGGTGGTGGT GTCCCGTGTG GCCCCTGTAT GCAAGAATGA TGTGGCGGGC 840
TCCCCACGGG TGCTGGAGAA GCAGTGGACT TCCTTCCTGA AGGCCCGGCT CAACTGCTCC 900
GTGCCTGGGG ACTCACACTT CACTTCAAT GTACTGCAGG CTGTGACTGG TGTGGTGAGC 960
CTTGGCGGCC GTCCAGTGAT TCTTGCTGTC TTCTCAACTC CTAGCAACAG CATCCCTGGC 1020
TCAGCTGTCT GTGCCTTTGA CATGAACCAA GTGGCTGCTG TGTTTGAAGG CCGCTTCCGG 1080
GAGCAGAAGT CACCTGAGTC AATCTGGACC CCAGTGCCTG AGGACCAAGT ACCACGGCCC 1140
AGGCCCGGGT GCTGTGCAGC GCCCGGTATG CAGTACAACG CATCCAATGC CCTTCCTGAC 1200
GAGATTCTCA ACTTTGTAAA GACCCACCCA CTGATGGACG AAGCGGTGCC CTCCCTGGGC 1260

CACTCGCCTT GGATTGTGAG AACTCTGATA CGGCACCAGC TGACCCGAGT GGCTGTGGAT 1320
 GTGGGTGCAG GCCCATGGGG CAATCAGACA ATAGTCTTCC TTGGCTCTGA GGTTCGCACA 1380
 5 GTCTCAAAT TCCTTGTA GCGCAATGCC AGTGTCTCAG GGACCACAGG GCCCAGCATC 1440
 TTTTGGAGG AGTTTGAGAC CTACCGGCCA GACAGGTGTG GACGATCCAG CAGTGCTGGT 1500
 10 GAGTGGGGAC AACGACTTCT GAGCCTGGAG CTAGATGCTG CCTCAGGTGG CCTGCTGGCA 1560
 GCCTTCCCCC GCTGTGTGGT TCGTGTTCCT GTTGCCCGCT GCCAGCTGTA CTCGGGGTGC 1620
 ATGAAGAACT GCATTGGCAG CCAAGATCCA TACTGCGGGT GGGCCCCCGA TGGCTCCTGC 1680
 15 ATCTTCCTCA GACCAGGAAC CAGTGCCACG TTTGAGCAAG ATGTGTCCGG GGCCAGCACC 1740
 TCTGGCTTAG GTGACTGCAC TGGACTCTTG CGCGCCAGCC TCTCAGATGA CCGCGCAGGG 1800
 20 CTGGTATCGG TGAACCTGCT GGTGACGTCC TCGGTGGCAG CGTTCGTGGT GGGTGCCGTG 1860
 GTGTCCGGTT TCAGCGTGGG CTGGTTCGTG GGTCTCCGG AGCGGCGGGA GCTGGCCCGG 1920
 CGCAAGGACA AGGAAGCCAT CCTGGCGCAT GCGGGCAGCG AGGCAGTGCT GAGCGTGAGC 1980
 25 CGACTGGGCG AGCGCAGGGG AACCGGGA CTGGGGTCTG GGGGAGCCGG CGGCGGTCCC 2040
 GGGGGTCCCC CGGAGGCCCT GCTGGCCCG CTTATGCAGA ATGGCTGGAC AAAGGCGGCA 2100
 30 CTGCTGCATG GTGGTCCTCA CGACCTGGAT TCGGGGCTGC TGCCCACCCC TGAGCAGACG 2160
 CCTTGCCCC AGAAACGCCT GCCACAACA CACCCACACG CCCACGCCCT AGGACCGCGA 2220
 GCCTGGGACC ACAGCCACGC GCTGCTGTG GCCTCTGCCT CCACATCCTT GCTCCTGCTG 2280
 35 GCGCACACCC GCGCCCCTGA GCAGCCCCA GTGCCGACTG AGTCAGGCCC GGAATCTCGC 2340
 CTCTGCGCCC CAAGATCCTG CCGGGCCTCT CACCCAGGCG ACTTCCCACT CACGCCTCAC 2400
 40 GCCAGCCCGG ACCGCCGGCG GGTGTGTCC GCACCCACGG GCCCCTTGA CTCTTCTTCG 2460
 GTGGGCGACG ACCTTCAGG GCCATGGAGC CCACCTGCAA CCAGCAGCCT GCGGAGGCCG 2520
 GGGCCCCATG GGGCCCCAAC AGCCGCCCTG CGGCGCACAC ACACATTCAA CAGCGGCGAG 2580
 45 GCGAGGCCCG GGGGTACCG TCCTGCGGC CACGCACCCG CGGACTCTAC ACATTGCTG 2640
 CCCTGCGGGA CGGGCGAGCG GACTGCACCC CCGGTACCCT AGGCCGGGCG GATGCCTCGA 2700
 50 CGGTGCCAAC CACAGCGACC CGGGCGTCAG CCCAGGTAC CGAGCCCTAC TGGCGCCGAG 2760
 TGGGACGCGT TCGTTCCCCA CCCTCGCGGG TGGGATCTC CTCGCCACAG GGAAGCACAA 2820
 55

5
10
15
20
25
30

GAGCCCCCTC CATCCCGGAA GATGCAGAAC ATGAAGCCCC GGGGTGGGCG GGAAGAGGCT 2880
GACCTTTTAC CTGAGCATAG ACTTTGATTT GTGTTTATTG TGAGTTTGGT TTTTTTTTTT 2940
TTCTAAGAAA TTGCACAGCC CCATTCTTAC TTGGGGTGTC GGCCGGGGTG GGAGGTGAGG 3000
ATATGGGGTA ACGGGAGGCA GAGCTGCAGA CACGAGCCTT CCTGCCTCAA CACATCCTCC 3060
CTAGAAGGGA CCCCTCCCC TTTCTGGGC TCCTGCGCGC GCGCGCGCGC GCGCGCGTGT 3120
GTGTGTGTGT GTGTGTGTGT GTGTCCGTGT GCATGGCCTG TTTGTGTGCA AAGGCCCGAG 3180
GCAGAAGTAT GTGTGCGTGC GTGTGAGACA GGGCTCCCGT GTGTGTGTGT GTGTGTGTGT 3240
GTGTGTGTGT GTGTGTGTGT GTGCGACTCA GAATGTGGGT GGTGGTGCCC TCAGAGACCC 3300
TGGCATTGGC TGAGCCAATG TTGGTACTTC TGGAAAGAAA CCCAGGGGAT GGAGCCTCTG 3360
AGGTGCCGGT TGGAGTTCAA ATCCTGCTCC TGCAGAGGGA ATCTGGGGAT CCAGGCTGGG 3420
AGATGGGGGA ACCTACTTCT AAAGGGCTTG TGGGGGGTTT TGGGAGGGTG GAAGTGGGCA 3480
GACACCCCTG TAAATACAGC CCTGGGGTGG TCAGAGAGGC CCATGCCACC TGTCCCCACT 3540
TGTGACATGC CCTCTGACTG CCAACTGACC ATGCATGCCA CGTGGCCAGC TGAGTCAGG 3600
ACCCTCCTCA GCCCTATCCC TGTCAATAAA ACTCTTGTTT ACATCCACCG CCCAA/AAAA 3660
AAAAAAAAA AAAAAAAAAA AAAAAAAAAA AA 3692

35
40
45

SEQ ID NO: 2

SEQUENCE LENGTH: 2664 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: No

ANTI-SENSE: No

50
55

ORIGINAL SOURCE:

ORGANISM: rat (*Rattus norvegicus*)

STRAIN: Wistar

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..2664

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

ATGTGGACCC CGCGAGCGCC CCCTCCACGC CCGGCCCTGC TGTTCCTCCT GCTGTTGCTT 60
CTGAGGGTCA CCCATGGCCT TTCCAGAT GAACCACCTC CACTCAGTGT GGCTCCCAGG 120
GACTACCTGA GCCACTACCC CGTGTTCGTG GGCAGCGGGC CTGGTCGTCT GACCCCTGCA 180
GAGGGTGCTG AGGACCTCAA CATCCAGAGA GTGCTACGTG TTAACAGGAC ACTGTTTCATC 240
GGGGACAGAG ACAACCTGTA CCAAGTAGAA CTGGAGCCAT CCACATCCAC GGAGCTGCGG 300
TATCAGCGGA AGCTTACCTG GCGTCCAAC CCCAGTGACA TCGATGTGTG TCGGATGAAG 360
GGCAAGCAAG AGGGTGAGTG TCGGAAC TTT GTCAAGGTGC TCCTGCTTCG TGACGAATCC 420
ACGCTCTTCG TGTGCGGCTC CAATGCATTC AATCCCATCT GTGCCAATTA CAGTATGGAC 480
ACACTGCAGC TTCTTGGAGA CAACATCAGT GGTATGGCCC GCTGCCCCTA CGACCCCAAG 540
CATGCCAATG TCGCCCTCTT CTCAGATGGG ATGCTCTTCA CAGCCACAGT AACTGACTTC 600
CTAGCCATCG ACGCTGTTAT CTACCGTAGC CTTGGGGACC GGCCACACT GCGCACAGTA 660
AAGCATGACT CCAAGTGGTT TAAAGAGCCA TACTTTGTGC ATGCGGTGGA GTGGGGAAGC 720
CACGTCTACT TCTTCTCCG GGAGATCGCC ATGGAGTTA ACTATCTGGA AAAGGTGGTG 780
GTGTCCCGTG TGGCCCGTGT ATGCAAGAAT GATGTGGGCG GCTCCCCACG GGTGCTGGAG 840
AAGCAGTGGA CTTCCTTCCT GAAGGCCCCG CTCAACTGCT CCGTGCCTGG GGA CTACAC 900
TTCTACTTCA ATGTACTGCA GGCTGTGACT GGTGTGGTGA GCCTTGGCGG CCGTCCAGTG 960
ATTCTTGCTG TCTTCTCAAC TCCTAGCAAC AGCATCCCTG GCTCAGCTGT CTGTGCCTTT 1020
GACATGAACC AAGTGGCTGC TGTGTTTGAA GGCCGCTTCC GGGAGCAGAA GTCACCTGAG 1080

TCAATCTGGA CCCAGTGCC TGAGGACCAA GTACCACGGC CCAGGCCCGG GTGCTGTGCA 1140
 5 GCGCCCGGTA TGCAGTACAA CGCATCCAAT GCCCTTCCTG ACGAGATTCT CAACTTTGTA 1200
 AAGACCCACC CACTGATGGA CGAAGCGGTG CCCTCCCTGG GCCACTCGCC TTGGATTGTG 1260
 AGAACTCTGA TACGGCACCA GCTGACCCGA GTGGCTGTGG ATGTGGGTGC AGGCCCATGG 1320
 10 GGCAATCAGA CAATAGTCTT CCTTGGCTCT GAGGTTGGCA CAGTCCTCAA ATTCCTTGTG 1380
 AAGCCCAATG CCAGTGTCTC AGGGACCACA GGGCCCAGCA TCTTTTGGGA GGAGTTTGAG 1440
 15 ACCTACCGGC CAGACAGGTG TGGACGATCC AGCAGTGCTG GTGAGTGGGG ACAACGACTT 1500
 CTGAGCCTGG AGCTAGATGC TGCCTCAGGT GGCCTGCTGG CAGCCTTCCC CCGCTGTGTG 1560
 GTTCGTGTTT CTGTTGCCCC CTGCCAGCTG TACTCGGGGT GCATGAAGAA CTGCATTGGC 1620
 20 AGCCAAGATC CATACTGCGG GTGGGCCCCC GATGGCTCCT GCATCTTCCT CAGACCAGGA 1680
 ACCAGTGCCA CGTTTGAGCA AGATGTGTCC GGGGCCAGCA CCTCTGGCTT AGGTGACTGC 1740
 ACTGGACTCT TGC GCGCCAG CCTCTCAGAT GACCGCGCAG GGCTGGTATC GGTGAACCTG 1800
 25 CTGGTGACGT CCTCGGTGGC AGCGTTCGTG GTGGGTGCCG TGGTGTCCGG TTTCAGCGTG 1860
 GGCTGGTTCG TGGGTCTCCG CGAGCGGCGG GAGCTGGCCC GCGCAAGGA CAAGGAAGCC 1920
 30 ATCTTGCGC ATGGCGGCAG CGAGGCAGTG CTGAGCGTGA GCCGACTGGG CGAGCGCAGG 1980
 GGAACCGGGA CTGGGGGTCTG TGGGGGAGCC GCGGGCGGTC CCGGGGTCC CCCGGAGGCC 2040
 CTGCTGGCCC CGCTTATGCA GAATGGCTGG ACAAAGGCGG CACTGCTGCA TGGTGGTCCT 2100
 35 CACGACCTGG ATTCGGGGCT GCTGCCACC CCTGAGCAGA CGCCTCTGCC CCAGAAACGC 2160
 CTGCCACAA CACACCCACA CGCCACGCC CTAGGACCGC GAGCCTGGA CCACAGCCAC 2220
 40 GCGCTGCTGT CGGCCTCTGC CTCCACATCC TTGCTCCTGC TGGCGCACAC CCGCGCCCCT 2280
 GAGCAGCCCC CAGTGCCGAC TGAGTCAGGC CCGGAATCTC GCCTCTGCGC CCCAAGATCC 2340
 TGCCGGGCCT CTCACCCAGG CGACTTCCCA CTCACGCTC ACGCCAGCCC GGACCGCCGG 2400
 45 CGGGTTGTGT CCGCACCCAC GGGCCCTTG GACTCTTCTT CGGTGGGCGA CGACCTTCCA 2460
 GGGCCATGGA GCCCACCTGC AACCAGCAGC CTGCGGAGGC CGGGCCCCCA TGGGCCCCCA 2520
 50 ACAGCCGCCC TCGGCGGCAC ACACACATTC AACAGCGGCG AGGCGAGGCC CGGGGGTCAC 2580
 CGTCCTCGCC GCCACGCACC CCGGACTCT ACACACTTGC TGCCCTGCGG GACGGGCGAG 2640

55

CGGACTGCAC CCCCAGTACC CTAG

2664

5

SEQ ID NO: 3

SEQUENCE LENGTH: 887 amino acids

10

SEQUENCE TYPE: amino acid

TOPOLOGY: linear

15

MOLECULE TYPE: peptide

ORIGINAL SOURCE:

ORGANISM: rat (Rattus norvegicus)

20

STRAIN: Wistar

TISSUE TYPE: brain

FEATURE:

25

FEATURE KEY: peptide

LOCATION: 1..887

30

IDENTIFICATION METHOD: P

SEQUENCE DESCRIPTION:

35

Met Trp Thr Pro Arg Ala Pro Pro Pro Arg Pro Ala Leu Leu Phe Leu

1 5 10 15

40

Leu Leu Leu Leu Arg Val Thr His Gly Leu Phe Pro Asp Glu Pro

20 25 30

45

Pro Pro Leu Ser Val Ala Pro Arg Asp Tyr Leu Ser His Tyr Pro Val

35 40 45

Phe Val Gly Ser Gly Pro Gly Arg Leu Thr Pro Ala Glu Gly Ala Glu

50

50 55 60

Asp Leu Asn Ile Gln Arg Val Leu Arg Val Asn Arg Thr Leu Phe Ile

55

EP 0 896 058 A1

	65	70	75	80
5	Gly Asp Arg Asp Asn Leu Tyr Gln Val Glu Leu Glu Pro Ser Thr Ser			
	85	90	95	
	Thr Glu Leu Arg Tyr Gln Arg Lys Leu Thr Trp Arg Ser Asn Pro Ser			
10	100	105	110	
	Asp Ile Asp Val Cys Arg Met Lys Gly Lys Gln Glu Gly Glu Cys Arg			
	115	120	125	
15	Asn Phe Val Lys Val Leu Leu Leu Arg Asp Glu Ser Thr Leu Phe Val			
	130	135	140	
20	Cys Gly Ser Asn Ala Phe Asn Pro Ile Cys Ala Asn Tyr Ser Met Asp			
	145	150	155	160
	Thr Leu Gln Leu Leu Gly Asp Asn Ile Ser Gly Met Ala Arg Cys Pro			
25	165	170	175	
	Tyr Asp Pro Lys His Ala Asn Val Ala Leu Phe Ser Asp Gly Met Leu			
30	180	185	190	
	Phe Thr Ala Thr Val Thr Asp Phe Leu Ala Ile Asp Ala Val Ile Tyr			
	195	200	205	
35	Arg Ser Leu Gly Asp Arg Pro Thr Leu Arg Thr Val Lys His Asp Ser			
	210	215	220	
40	Lys Trp Phe Lys Glu Pro Tyr Phe Val His Ala Val Glu Trp Gly Ser			
	225	230	235	240
	His Val Tyr Phe Phe Phe Arg Glu Ile Ala Met Glu Phe Asn Tyr Leu			
45	245	250	255	
	Glu Lys Val Val Val Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val			
50	260	265	270	
	Gly Gly Ser Pro Arg Val Leu Glu Lys Gln Trp Thr Ser Phe Leu Lys			

55

EP 0 896 058 A1

	275	280	285
5	Ala Arg Leu Asn Cys Ser Val Pro Gly Asp Ser His Phe Tyr Phe Asn		
	290	295	300
	Val Leu Gln Ala Val Thr Gly Val Val Ser Leu Gly Gly Arg Pro Val		
10	305	310	315 320
	Ile Leu Ala Val Phe Ser Thr Pro Ser Asn Ser Ile Pro Gly Ser Ala		
	325	330	335
15	Val Cys Ala Phe Asp Met Asn Gln Val Ala Ala Val Phe Glu Gly Arg		
	340	345	350
20	Phe Arg Glu Gln Lys Ser Pro Glu Ser Ile Trp Thr Pro Val Pro Glu		
	355	360	365
	Asp Gln Val Pro Arg Pro Arg Pro Gly Cys Cys Ala Ala Pro Gly Met		
25	370	375	380
	Gln Tyr Asn Ala Ser Asn Ala Leu Pro Asp Glu Ile Leu Asn Phe Val		
30	385	390	395 400
	Lys Thr His Pro Leu Met Asp Glu Ala Val Pro Ser Leu Gly His Ser		
	405	410	415
35	Pro Trp Ile Val Arg Thr Leu Ile Arg His Gln Leu Thr Arg Val Ala		
	420	425	430
40	Val Asp Val Gly Ala Gly Pro Trp Gly Asn Gln Thr Ile Val Phe Leu		
	435	440	445
45	Gly Ser Glu Val Gly Thr Val Leu Lys Phe Leu Val Lys Pro Asn Ala		
	450	455	460
	Ser Val Ser Gly Thr Thr Gly Pro Ser Ile Phe Leu Glu Glu Phe Glu		
50	465	470	475 480
	Thr Tyr Arg Pro Asp Arg Cys Gly Arg Ser Ser Ser Ala Gly Glu Trp		
55			

	485	490	495
5	Gly Gln Arg Leu Leu Ser Leu Glu Leu Asp Ala Ala Ser Gly Gly Leu		
	500	505	510
	Leu Ala Ala Phe Pro Arg Cys Val Val Arg Val Pro Val Ala Arg Cys		
10	515	520	525
	Gln Leu Tyr Ser Gly Cys Met Lys Asn Cys Ile Gly Ser Gln Asp Pro		
15	530	535	540
	Tyr Cys Gly Trp Ala Pro Asp Gly Ser Cys Ile Phe Leu Arg Pro Gly		
	545	550	555
20	Thr Ser Ala Thr Phe Glu Gln Asp Val Ser Gly Ala Ser Thr Ser Gly		
	565	570	575
	Leu Gly Asp Cys Thr Gly Leu Leu Arg Ala Ser Leu Ser Asp Asp Arg		
25	580	585	590
	Ala Gly Leu Val Ser Val Asn Leu Leu Val Thr Ser Ser Val Ala Ala		
30	595	600	605
	Phe Val Val Gly Ala Val Val Ser Gly Phe Ser Val Gly Trp Phe Val		
	610	615	620
35	Gly Leu Arg Glu Arg Arg Glu Leu Ala Arg Arg Lys Asp Lys Glu Ala		
	625	630	635
40	Ile Leu Ala His Gly Gly Ser Glu Ala Val Leu Ser Val Ser Arg Leu		
	645	650	655
	Gly Glu Arg Arg Gly Thr Gly Thr Gly Gly Arg Gly Gly Ala Gly Gly		
45	660	665	670
	Gly Pro Gly Gly Pro Pro Glu Ala Leu Leu Ala Pro Leu Met Gln Asn		
50	675	680	685
	Gly Trp Thr Lys Ala Ala Leu Leu His Gly Gly Pro His Asp Leu Asp		

55

	690	695	700	
5	Ser Gly Leu Leu Pro Thr Pro Glu Gln Thr Pro Leu Pro Gln Lys Arg			
	705	710	715	720
	Leu Pro Thr Thr His Pro His Ala His Ala Leu Gly Pro Arg Ala Trp			
10		725	730	735
	Asp His Ser His Ala Leu Leu Ser Ala Ser Ala Ser Thr Ser Leu Leu			
15		740	745	750
	Leu Leu Ala His Thr Arg Ala Pro Glu Gln Pro Pro Val Pro Thr Glu			
	755	760	765	
20	Ser Gly Pro Glu Ser Arg Leu Cys Ala Pro Arg Ser Cys Arg Ala Ser			
	770	775	780	
25	His Pro Gly Asp Phe Pro Leu Thr Pro His Ala Ser Pro Asp Arg Arg			
	785	790	795	800
	Arg Val Val Ser Ala Pro Thr Gly Pro Leu Asp Ser Ser Ser Val Gly			
30		805	810	815
	Asp Asp Leu Pro Gly Pro Trp Ser Pro Pro Ala Thr Ser Ser Leu Arg			
35		820	825	830
	Arg Pro Gly Pro His Gly Pro Pro Thr Ala Ala Leu Arg Arg Thr His			
40		835	840	845
	Thr Phe Asn Ser Gly Glu Ala Arg Pro Gly Gly His Arg Pro Arg Arg			
	850	855	860	
45	His Ala Pro Ala Asp Ser Thr His Leu Leu Pro Cys Gly Thr Gly Glu			
	865	870	875	880
50	Arg Thr Ala Pro Pro Val Pro			
	885			
55				

SEQ ID NO: 4

SEQUENCE LENGTH: 3524 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: No

ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: human (Homo sapiens)

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: 5'UTR

LOCATION: 1..38

IDENTIFICATION METHOD: E

FEATURE KEY: CDS

LOCATION: 39..2702

IDENTIFICATION METHOD: E

FEATURE KEY: 3'UTR

LOCATION: 2706..3524

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

TCCGAGGCGT CACCTCCTCC TGTCCGCTGG CCCTCGCCAT GCAGACCCCG CGAGCGTCCC 60

CTCCCCGCCC GGGCCTGCTG CTTCTGCTGC TGCTACTGGG GGGCGCCAC GGCCTCTTTC 120
 5 CTGAGGACCC GCCGCCGCTT AGCGTGGCCC CCAGGGACTA CCTGAACCAC TATCCCGTGT 180
 TTGTGGGCAG CGGGCCCGGA CGCCTGACCC CCGCAGAAGG TGCTGACGAC CTCAACATCC 240
 AGCGAGTCCT GCGGGTCAAC AGGACGCTGT TCATTGGGGA CAGGGACAAC CTCTACCGCG 300
 10 TAGAGCTGGA GCCCCCACG TCCACGGAGC TGCGGTACCA GAGGAAGCTG ACCTGGAGAT 360
 CTAACCCAG CGACATAAAC GTGTGTCGGA TGAAGGGCAA ACAGGAGGGC GAGTGTGCAA 420
 15 ACTTCGTAAA GGTGCTGCTC CTTCGGGACG AGTCCACGCT CTTTGTGTGC GGTTCACACG 480
 CCTTCAACCC GGTGTGCGCC AACTACAGCA TAGACACCCT GCAGCCCGTC GGAGACAACA 540
 TCAGCGGTAT GGGCCGCTGC CCGTACGACC CCAAGCACGC CAATGTTGCC CTCTTCTCTG 600
 20 ACGGGATGCT CTTACAGCT ACTGTTACCG ACTTCCTAGC CATTGATGCT GTCATCTACC 660
 GCAGCCTCGG GGACAGGCCC ACCCTGCGCA CCGTGAAACA TGACTCCAAG TGGTTCAAAG 720
 25 AGCCTTACTT TGTCCATGCG GTGGAGTGGG GCAGCCATGT CTACTTCTTC TTCCGGGAGA 780
 TTGCGATGGA GTTAACTAC CTGGAGAAGG TGGTGGTGTC CCGCGTGGCC CGAGTGTGCA 840
 AGAACGACGT GGGAGGCTCC CCCCGCGTGC TGGAGAAGCA GTGGACGTCC TTCCTGAAGG 900
 30 CGCGGCTCAA CTGCTCTGTA CCCGGAGACT CCCATTTCTA CTTCAACGTG CTGCAGGCTG 960
 TCACGGGCGT GGTGAGCCTC GGGGGCCGGC CCGTGGTCCT GGCCGTTTTT TCCACGCCCA 1020
 GCAACAGCAT CCCTGGCTCG GCTGTCTGCG CCTTTGACCT GACACAGGTG GCAGCTGTGT 1080
 35 TTGAAGGCCG CTTCCGAGAG CAGAAGTCCC CCGAGTCCAT CTGGACGCCG GTGCCGGAGG 1140
 ATCAGGTGCC TCGACCCCGG CCCGGGTGCT GCGCAGCCCC CGGGATGCAG TACAATGCCT 1200
 40 CCAGCGCCTT GCCGGATGAC ATCCTCAACT TTGTCAAGAC CCACCCTCTG ATGGACGAGG 1260
 CGGTGCCCTC GCTGGGCCAT GCGCCCTGGA TCCTGCGGAC CCTGATGAGG CACCAGCTGA 1320
 CTCGAGTGGC TGTGGACGTG GGAGCCGGCC CCTGGGGCAA CCAGACCGTT GTCTTCCTGG 1380
 45 GTTCTGAGGC GGGGACGGTC CTCAAGTTCC TCGTCCGGCC CAATGCCAGC ACCTCAGGGA 1440
 CGTCTGGGCT CAGTGTCTTC CTGGAGGAGT TTGAGACCTA CCGGCCGGAC AGGTGTGGAC 1500
 50 GGCCCGGCGG TGGCGAGACA GGGCAGCGGC TGCTGAGCTT GGAGCTGGAC GCAGCTTCGG 1560
 GGGGCTGCT GGCTGCCTTC CCCCGCTGCG TGGTCCGAGT GCCTGTGGCT CGCTGCCAGC 1620
 55

AGTACTCGGG GTGTATGAAG AACTGTATCG GCAGTCAGGA CCCCTACTGC GGGTGGGCCC 1680
5 CCGACGGCTC CTGCATCTTC CTCAGCCCGG GCACCAGAGC CGCCTTTGAG CAGGACGTGT 1740
CCGGGGCCAG CACCTCAGGC TTAGGGGACT GCACAGGACT CCTGCGGGCC AGCCTCTCCG 1800
AGGACCGCGC GGGGCTGGTG TCGGTGAACC TGCTGGTAAC GTCGTGGTG GCGGCCTTCG 1860
10 TGGTGGGAGC CGTGGTGTCC GGCTTCAGCG TGGGCTGGTT CGTGGGCCTC CGTGAGCGGC 1920
GGGAGCTGGC CCGGCGCAAG GACAAGGAGG CCATCCTGGC GCACGGGGCG GGCAGGGCGG 1980
TGCTGAGCGT CAGCCGCCTG GCGGAGCGCA GGGCGCAGGG TCCCGGGGGC CGGGGCGGAG 2040
15 GCGGTGGCGG TGGCGCCGGG GTTCCCCCGG AGGCCTGCT GGCGCCCTG ATGCAGAACG 2100
GCTGGGCCAA GGCCACGCTG CTGCAGGGCG GGCCCCACGA CCTGGACTCG GGGCTGCTGC 2160
20 CCACGCCCGA GCAGACGCCG CTGCCGAGA AGCGCTGCC CACTCCGCAC CCGCACCCCC 2220
ACGCCCTGGG CCCCCGCGCC TGGGACCACG GCCACCCCT GCTCCCGGCC TCCGCTTCAT 2280
CCTCCCTCCT GCTGCTGGCG CCCGCCCGG CCCCCGAGCA GCCCCCGCG CCTGGGGAGC 2340
25 CGACCCCCGA CGGCCGCTC TATGCTGCCC GGCCCGGCG CGCCTCCAC GCGGACTTCC 2400
CGCTACCCCC CCACGCCAGC CCGGACCGC GCGGGGTGGT GTCCGCGCCC ACGGGCCCT 2460
30 TGGACCCAGC CTCAGCCGCC GATGGCCTCC CGCGGCCCTG GAGCCCGCCC CCGACGGGCA 2520
GCCTGAGGAG GCCACTGGGC CCCCACGCC CTCCGGCCGC CACCCTGCGC CGCACCCACA 2580
CGTTCAACAG CGGCGAGGCC CGGCCTGGG ACCGCCACG CGGCTGCCAC GCGCGGCCG 2640
35 GCACAGACTT GGCCACCTC CTCCCTATG GGGGGGCGGA CAGGACTGCG CCCCCGTGC 2700
CCTAGGCCGG GGGCCCCCG ATGCCTTGGC AGTGCCAGC ACGGGAACCA GGAGCGAGAG 2760
40 ACGGTGCCAG AACGCCGGG CCGGGGCAA CTCCGACTGG GTGCTCAAGT CCCCCCGCG 2820
ACCAACCGC GGAGTGGGG GCCCCCTCG CCACAAAGAA GCACAACCAG CTCGCCCTCC 2880
CCCTACCCGG GGCCGAGGA CGCTGAGACG GTTTGGGGT GGGTGGGCGG GAGGACTTTG 2940
45 CTATGGATTT GAGGTTGACC TTATGCGGT AGGTTTGGT TTTTTTGCA GTTTTGGTTT 3000
CTTTTGGGT TTTCTAACCA ATTGCACAAC TCCGTTCTCG GGGTGGCGC AGGCAGGGGA 3060
50 GGCTTGGACG CCGTGGGGA ATGGGGGCC ACAGCTGCAG ACCTAAGCCC TCCCCACCC 3120
CTGGAAGGT CCCTCCCCA CCCAGGCCC TGGCGTGTG GGGTGTGCGT GCGTGTGCGT 3180

5 GCCGTGTTTCG TGTGCAAGGG GCCGGGGAGG TGGGCGTGTG TGTGCGTGCC AGCGAAGGCT 3240
GCTGTGGGCG TGTGTGTCAA GTGGGCCACG CGTGCCAGGT GTGTGTCCAC GAGCGACGAT 3300
CGTGGTGGCC CCAGCGGCCT GGGCGTTGGC TGAGCCGACG CTGGGGCTTC CAGAAGGCCC 3360
GGGGGTCTCC GAGGTGCCGG TTAGGAGTTT GAACCCCCC CACTCTGCAG AGGGAAGCGG 3420
10 GGACAATGCC GGGGTTTCAG GCAGGAGACA CGAGGAGGGC CTGCCCGGAA GTCACATCGG 3480
CAGCAGCTGT CTAAAGGGCT TGGGGGCCTG GGGGGCGGCG AAAG 3524

15 SEQ ID NO: 5

SEQUENCE LENGTH: 2667 base pairs

20 SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

25 MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: No

30 ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: human (Homo sapiens)

35 TISSUE TYPE: brain

FEATURE:

40 FEATURE KEY: CDS

LOCATION: 1..2667

IDENTIFICATION METHOD: E

45 SEQUENCE DESCRIPTION:

50 ATGCAGACCC CGCGAGCGTC CCCTCCCCGC CCGGCCCTGC TGCTTCTGCT GCTGCTACTG 60
GGGGGCGCCC ACGGCCTCTT TCCTGAGGAC CCGCCGCCGC TTAGCGTGGC CCCCAGGGAC 120

TACCTGAACC ACTATCCCGT GTTTGTGGGC AGCGGGCCCG GACGCCTGAC CCCCCAGAA 180
 5 GGTGCTGACG ACCTCAACAT CCAGCGAGTC CTGCGGGTCA ACAGGACGCT GTTCATTGGG 240
 GACAGGGACA ACCTCTACCG CGTAGAGCTG GAGCCCCCA CGTCCACGGA GCTGCGGTAC 300
 CAGAGGAAGC TGACCTGGAG ATCTAACCCC AGCGACATAA ACGTGTGTCG GATGAAGGGC 360
 10 AAACAGGAGG GCGAGTGTCT AACTTTCGTA AAGGTGCTGC TCCTTCGGGA CGAGTCCACG 420
 CTCTTTGTGT GCGGTTCCAA CGCCTTCAAC CCGGTGTGCG CCAACTACAG CATAGACACC 480
 CTGCAGCCCG TCGGAGACAA CATCAGCGGT ATGGCCCGCT GCCCGTACGA CCCCAGCAC 540
 15 GCCAATGTTG CCCTCTTCTC TGACGGGATG CTCTTCACAG CTACTGTTAC CGACTTCCTA 600
 GCCATTGATG CTGTCATCTA CCGCAGCCTC GGGGACAGGC CCACCCTGCG CACCGTGAAA 660
 20 CATGACTCCA AGTGGTTCOA AGAGCCTTAC TTTGTCCATG CGGTGGAGTG GGGCAGCCAT 720
 GTCTACTTCT TCTTCCGGGA GATTGCGATG GAGTTTAACT ACCTGGAGAA GGTGGTGGTG 780
 TCCCGCGTGG CCCGAGTGTG CAAGAACGAC GTGGGAGGCT CCCCCGCGT GCTGGAGAAG 840
 25 CAGTGGACGT CCTTCCTGAA GCGCGGGCTC AACTGCTCTG TACCCGAGA CTCCATTTC 900
 TACTTCAACG TGCTGCAGGC TGTCACGGGC GTGGTCAGCC TCGGGGGCCG GCCCGTGGTC 960
 30 CTGGCCGTTT TTTCCACGCC CAGCAACAGC ATCCCTGGCT CGGCTGTCTG CGCCTTTGAC 1020
 CTGACACAGG TGGCAGCTGT GTTTGAAGGC CGCTTCCGAG AGCAGAAGTC CCCCAGTCC 1080
 ATCTGGACGC CGGTGCCGGA GGATCAGGTG CCTCGACCCC GGCCCGGGTG CTGCGCAGCC 1140
 35 CCGGGGATGC AGTACAATGC CTCCAGCGCC TTGCCGATG ACATCCTCAA CTTTGTCAAG 1200
 ACCCACCTC TGATGGACGA GCGGCTGCC TCGCTGGGCC ATGCGCCCTG GATCCTGCGG 1260
 40 ACCCTGATGA GGCACCAGCT GACTCGAGTG GCTGTGGACG TGGGAGCCGG CCCCTGGGGC 1320
 AACCAGACCG TTGTCTTCTT GGGTTCTGAG GCGGGGACGG TCCTCAAGTT CCTCGTCCGG 1380
 CCAATGCCA GCACCTCAGG GACGTCTGGG CTGAGTGTCT TCCTGGAGGA GTTTGAGACC 1440
 45 TACCGGCCGG ACAGGTGTGG ACGGCCCGGC GGTGGCGAGA CAGGGCAGCG GCTGCTGAGC 1500
 TTGGAGCTGG ACGCAGCTTC GGGGGGCCCTG CTGGCTGCCT TCCCCGCTG CGTGGTCCGA 1560
 50 GTGCCTGTGG CTCGCTGCCA GCAGTACTCG GGGTGTATGA AGAACTGTAT CGGCAGTCAG 1620
 GACCCCTACT GCGGGTGGGC CCCCAGCGC TCCTGCATCT TCCTCAGCCC GGGCACCAGA 1680

55

GCCGCCTTTG AGCAGGACGT GTCCGGGGCC AGCACCTCAG GCTTAGGGGA CTGCACAGGA 1740
5 CTCCTGCGGG CCAGCCTCTC CGAGGACCCG GCGGGGCTGG TGTCGGTGAA CCTGCTGGTA 1800
ACGTCGTCCG TGGCGGCCTT CGTGGTGGGA GCCGTGGTGT CCGGCTTCAG CGTGGGCTGG 1860
TTCGTGGGCC TCCGTGAGCG GCGGGAGCTG GCCCGGCGCA AGGACAAGGA GGCCATCCTG 1920
10 GCGCACGGGG CCGGCGAGGC GGTGCTGAGC GTCAGCCGCC TGGGCGAGCG CAGGGCGCAG 1980
GGTCCCGGGG GCCGGGGCGG AGGCGGTGGC GGTGGCGCGG GGGTTCCCCC GGAGGCCCTG 2040
CTGGCGCCCC TGATGCAGAA CGGCTGGGCC AAGGCCACGC TGCTGCAGGG CGGGCCCCAC 2100
15 GACCTGGACT CGGGGCTGCT GCCCAGCCCC GAGCAGACGC CGCTGCCGCA GAAGCGCCTG 2160
CCCACTCCGC ACCCGCACCC CCACGCCCTG GGCCCCCGCG CCTGGGACCA CGGCCACCCC 2220
20 CTGCTCCCGG CCTCCGCTTC ATCTCCCTC CTGCTGCTGG CGCCCGCCCG GGCCCCGAG 2280
CAGCCCCCGG CGCCTGGGGA GCCGACCCCC GACGGCCGCC TCTATGCTGC CCGGCCCGGC 2340
CGCGCCTCCC ACGGCGACTT CCCGCTCACC CCCCAGCCA GCCCGGACCG CCGGCGGGTG 2400
25 GTGTCCGCGC CCACGGGCCC CTTGGACCCA GCCTCAGCCG CCGATGGCCT CCCGCGGCC 2460
TGGAGCCCGC CCCCACGGG CAGCCTGAGG AGGCCACTGG GCCCCACGC CCCTCCGGCC 2520
30 GCCACCCTGC GCCGCACCCA CACGTTCAAC AGCGGCGAGG CCCGGCCTGG GGACCGCCAC 2580
CGCGGCTGCC ACGCCCGGCC GGGCACAGAC TTGGCCACC TCCTCCCCTA TGGGGGGGCG 2640
35 GACAGGACTG CGCCCCCGT GCCCTAG 2667

SEQ ID NO: 6

40 SEQUENCE LENGTH: 888 amino acids

SEQUENCE TYPE: amino acid

45 TOPOLOGY: linear

MOLECULE TYPE: peptide

ORIGINAL SOURCE:

50 ORGANISM: human (Homo sapiens)

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: peptide

LOCATION: 1..888

IDENTIFICATION METHOD: P

SEQUENCE DESCRIPTION:

Met Gln Thr Pro Arg Ala Ser Pro Pro Arg Pro Ala Leu Leu Leu Leu
 1 5 10 15
 Leu Leu Leu Leu Gly Gly Ala His Gly Leu Phe Pro Glu Asp Pro Pro
 20 25 30
 Pro Leu Ser Val Ala Pro Arg Asp Tyr Leu Asn His Tyr Pro Val Phe
 35 40 45
 Val Gly Ser Gly Pro Gly Arg Leu Thr Pro Ala Glu Gly Ala Asp Asp
 50 55 60
 Leu Asn Ile Gln Arg Val Leu Arg Val Asn Arg Thr Leu Phe Ile Gly
 65 70 75 80
 Asp Arg Asp Asn Leu Tyr Arg Val Glu Leu Glu Pro Pro Thr Ser Thr
 85 90 95
 Glu Leu Arg Tyr Gln Arg Lys Leu Thr Trp Arg Ser Asn Pro Ser Asp
 100 105 110
 Ile Asn Val Cys Arg Met Lys Gly Lys Gln Glu Gly Glu Cys Arg Asn
 115 120 125
 Phe Val Lys Val Leu Leu Leu Arg Asp Glu Ser Thr Leu Phe Val Cys
 130 135 140
 Gly Ser Asn Ala Phe Asn Pro Val Cys Ala Asn Tyr Ser Ile Asp Thr
 145 150 155 160

5 165 170 175
 Leu Gln Pro Val Gly Asp Asn Ile Ser Gly Met Ala Arg Cys Pro Tyr
 Asp Pro Lys His Ala Asn Val Ala Leu Phe Ser Asp Gly Met Leu Phe
 10 180 185 190
 Thr Ala Thr Val Thr Asp Phe Leu Ala Ile Asp Ala Val Ile Tyr Arg
 195 200 205
 Ser Leu Gly Asp Arg Pro Thr Leu Arg Thr Val Lys His Asp Ser Lys
 15 210 215 220
 Trp Phe Lys Glu Pro Tyr Phe Val His Ala Val Glu Trp Gly Ser His
 20 225 230 235 240
 Val Tyr Phe Phe Phe Arg Glu Ile Ala Met Glu Phe Asn Tyr Leu Glu
 25 245 250 255
 Lys Val Val Val Ser Arg Val Ala Arg Val Cys Lys Asn Asp Val Gly
 260 265 270
 Gly Ser Pro Arg Val Leu Glu Lys Gln Trp Thr Ser Phe Leu Lys Ala
 30 275 280 285
 Arg Leu Asn Cys Ser Val Pro Gly Asp Ser His Phe Tyr Phe Asn Val
 35 290 295 300
 Leu Gln Ala Val Thr Gly Val Val Ser Leu Gly Gly Arg Pro Val Val
 40 305 310 315 320
 Leu Ala Val Phe Ser Thr Pro Ser Asn Ser Ile Pro Gly Ser Ala Val
 325 330 335
 45 340 345 350
 Cys Ala Phe Asp Leu Thr Gln Val Ala Ala Val Phe Glu Gly Arg Phe
 50 355 360 365
 Arg Glu Gln Lys Ser Pro Glu Ser Ile Trp Thr Pro Val Pro Glu Asp
 55

Gln Val Pro Arg Pro Arg Pro Gly Cys Cys Ala Ala Pro Gly Met Gln
 370 375 380
 Tyr Asn Ala Ser Ser Ala Leu Pro Asp Asp Ile Leu Asn Phe Val Lys
 385 390 395 400
 Thr His Pro Leu Met Asp Glu Ala Val Pro Ser Leu Gly His Ala Pro
 405 410 415
 Trp Ile Leu Arg Thr Leu Met Arg His Gln Leu Thr Arg Val Ala Val
 420 425 430
 Asp Val Gly Ala Gly Pro Trp Gly Asn Gln Thr Val Val Phe Leu Gly
 435 440 445
 Ser Glu Ala Gly Thr Val Leu Lys Phe Leu Val Arg Pro Asn Ala Ser
 450 455 460
 Thr Ser Gly Thr Ser Gly Leu Ser Val Phe Leu Glu Glu Phe Glu Thr
 465 470 475 480
 Tyr Arg Pro Asp Arg Cys Gly Arg Pro Gly Gly Gly Glu Thr Gly Gln
 485 490 495
 Arg Leu Leu Ser Leu Glu Leu Asp Ala Ala Ser Gly Gly Leu Leu Ala
 500 505 510
 Ala Phe Pro Arg Cys Val Val Arg Val Pro Val Ala Arg Cys Gln Gln
 515 520 525
 Tyr Ser Gly Cys Met Lys Asn Cys Ile Gly Ser Gln Asp Pro Tyr Cys
 530 535 540
 Gly Trp Ala Pro Asp Gly Ser Cys Ile Phe Leu Ser Pro Gly Thr Arg
 545 550 555 560
 Ala Ala Phe Glu Gln Asp Val Ser Gly Ala Ser Thr Ser Gly Leu Gly
 565 570 575

Asp Cys Thr Gly Leu Leu Arg Ala Ser Leu Ser Glu Asp Arg Ala Gly
 5 580 585 590
 Leu Val Ser Val Asn Leu Leu Val Thr Ser Ser Val Ala Ala Phe Val
 595 600 605
 10 Val Gly Ala Val Val Ser Gly Phe Ser Val Gly Trp Phe Val Gly Leu
 610 615 620
 15 Arg Glu Arg Arg Glu Leu Ala Arg Arg Lys Asp Lys Glu Ala Ile Leu
 625 630 635 640
 Ala His Gly Ala Gly Glu Ala Val Leu Ser Val Ser Arg Leu Gly Glu
 20 645 650 655
 Arg Arg Ala Gln Gly Pro Gly Gly Arg Gly Gly Gly Gly Gly Gly
 25 660 665 670
 Ala Gly Val Pro Pro Glu Ala Leu Leu Ala Pro Leu Met Gln Asn Gly
 675 680 685
 30 Trp Ala Lys Ala Thr Leu Leu Gln Gly Gly Pro His Asp Leu Asp Ser
 690 695 700
 35 Gly Leu Leu Pro Thr Pro Glu Gln Thr Pro Leu Pro Gln Lys Arg Leu
 705 710 715 720
 Pro Thr Pro His Pro His Pro His Ala Leu Gly Pro Arg Ala Trp Asp
 40 725 730 735
 His Gly His Pro Leu Leu Pro Ala Ser Ala Ser Ser Ser Leu Leu Leu
 45 740 745 750
 Leu Ala Pro Ala Arg Ala Pro Glu Gln Pro Pro Ala Pro Gly Glu Pro
 755 760 765
 50 Thr Pro Asp Gly Arg Leu Tyr Ala Ala Arg Pro Gly Arg Ala Ser His
 770 775 780
 55

Gly Asp Phe Pro Leu Thr Pro His Ala Ser Pro Asp Arg Arg Arg Val
 785 790 795 800
 Val Ser Ala Pro Thr Gly Pro Leu Asp Pro Ala Ser Ala Ala Asp Gly
 805 810 815
 Leu Pro Arg Pro Trp Ser Pro Pro Pro Thr Gly Ser Leu Arg Arg Pro
 820 825 830
 Leu Gly Pro His Ala Pro Pro Ala Ala Thr Leu Arg Arg Thr His Thr
 835 840 845
 Phe Asn Ser Gly Glu Ala Arg Pro Gly Asp Arg His Arg Gly Cys His
 850 855 860
 Ala Arg Pro Gly Thr Asp Leu Ala His Leu Leu Pro Tyr Gly Gly Ala
 865 870 875 880
 Asp Arg Thr Ala Pro Pro Val Pro
 885

SEQ ID NO: 7

SEQUENCE LENGTH: 176 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: double

TOPOLOGY: linear

MOLECULE TYPE: cDNA to mRNA

HYPOTHETICAL: No

ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: human (Homo sapiens)

TISSUE TYPE: hippocampus

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..176

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

CAGCGGCTGC TGAGCTTGA GCTGGACGCA GCTTCGGGGG GCCTGCTGGC TGCCTTCCCC 60
CGCTGCGTGG TCCGAGTGCC TGTGGCTCGC TGCCAGCAGT ACTCGGGGTG TATGAAGAAC 120
TGTATCGGCA GTCAGGACCC CTACTGCGGG TGGGCCCCCG ACGGCTCCTG CATCTT 176

SEQ ID NO: 8

SEQUENCE LENGTH: 18 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

HYPOTHETICAL: No

ANTI-SENSE: Yes

ORIGINAL SOURCE:

ORGANISM: human (Homo sapiens)

TISSUE TYPE: hippocampus

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..18

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

AAGATGCAGG AGCCGTCG

18

5

SEQ ID NO: 9

SEQUENCE LENGTH: 18 base pairs

10

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

15

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

HYPOTHETICAL: No

20

ANTI-SENSE: No

ORIGINAL SOURCE:

25

ORGANISM: human (Homo sapiens)

TISSUE TYPE: hippocampus

FEATURE:

30

FEATURE KEY: CDS

LOCATION: 1..18

35

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

CAGCGGCTGC TGAGCTTG

18

40

SEQ ID NO: 10²

SEQUENCE LENGTH: 21 base pairs

45

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

50

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

55

HYPOTHETICAL: No

ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: rat (*Rattus norvegicus*)

STRAIN: Wistar

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..21

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

TACTTCAATG TACTGCAGGC T 21

SEQ ID NO: 11

SEQUENCE LENGTH: 21 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

HYPOTHETICAL: No

ANTI-SENSE: Yes

ORIGINAL SOURCE:

ORGANISM: rat (*Rattus norvegicus*)

STRAIN: Wistar

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..21

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

AAGATGCAGG AGCCATCGGG G 21

SEQ ID NO: 12

SEQUENCE LENGTH: 18 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

HYPOTHETICAL: No

ANTI-SENSE: Yes

ORIGINAL SOURCE:

ORGANISM: rat (Rattus norvegicus)

STRAIN: SD

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..18

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

CAGGAACACG AACCCACAC 18

SEQ ID NO: 13

SEQUENCE LENGTH: 18 base pairs

SEQUENCE TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Other nucleic acid, synthetic DNA

HYPOTHETICAL: No

ANTI-SENSE: No

ORIGINAL SOURCE:

ORGANISM: rat (*Rattus norvegicus*)

STRAIN: SD

TISSUE TYPE: brain

FEATURE:

FEATURE KEY: CDS

LOCATION: 1..18

IDENTIFICATION METHOD: E

SEQUENCE DESCRIPTION:

GTATGCAAGA ATGATGTG

18

Claims

1. Semaphorin Z DNA comprising the nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 4.
2. Semaphorin Z open reading frame comprising the nucleotide sequence shown in SEQ ID NO: 2 or SEQ ID NO: 5.
3. Semaphorin Z protein comprising the amino acid sequence shown in SEQ ID NO: 3 or SEQ ID NO: 6.
4. A DNA which encodes a protein having Semaphorin domain and which hybridizes under stringent conditions to DNA comprising the nucleotide sequence shown in SEQ ID NO: 7.
5. A protein encoded by the DNA of claim 4.
6. A DNA which encodes a protein inhibiting neurite outgrowth and which hybridizes under stringent conditions to DNA of claim 1.

7. A DNA of claim 6 which encodes a protein inhibiting neurite outgrowth of CNS-neuron.
8. A protein encoded by the DNA of claim 6 or 7.
- 5 9. A DNA which encodes a protein inhibiting neurite outgrowth, said protein containing insertions, deletions, or substitutions of one or more amino acids in the protein of claim 3.
10. A DNA of claim 9 which encodes a protein inhibiting neurite outgrowth of CNS-neuron.
- 10 11. A protein encoded by the DNA of claim 9 or 10.
12. A DNA which encodes a protein promoting neurite outgrowth of CNS-neuron, said protein containing insertions, deletions, or substitutions of one or more amino acids in the protein of claim 3.
- 15 13. A protein encoded by the DNA of claim 12.
14. A DNA which is cloned from a human cDNA library or a human genomic library, and which hybridizes under stringent conditions to DNA comprising at least part of the DNA of claim 1 or at least part of the complementary strand thereof.
- 20 15. An expression plasmid expressing one of the DNAs of claim 1, 2, 4, 6, 7, 9, 10, 12, or 14.
16. A transformant transformed with the expression plasmid of claim 15.
- 25 17. A process for producing a recombinant protein, said process being characterized in that the transformant of claim 16 is cultured under conditions that allow expression of the expression plasmid of claim 15.
18. A polypeptide comprising a fragment consisting of at least 6 amino acids of one of the proteins of claims 3, 5, 8, 11, or 13.
- 30 19. A polypeptide of claim 18 which promotes neurite outgrowth of CNS-neuron.
20. A polypeptide of claim 18 characterized in that it contains aspartic acid at position 203 of the amino acid sequence shown in SEQ ID NO: 6 or an amino acid corresponding to the position of said aspartic acid.
- 35 21. A DNA or RNA comprising 8 or more bases, or a chemically modified variant thereof, which has a sequence complementary to one of the DNAs of claims 1, 4, 6, 7, or 14.
22. A DNA or RNA of claim 21, or a chemically modified variant thereof, characterized in that it inhibits an expression of one of the proteins of claims 3, 5, or 8.
- 40 23. An antibody against one of the proteins of claims 3, 5, 8, 11, or 13, or against one of the polypeptides of claims 18-20.
- 45 24. A screening method for Semaphorin Z inhibitor, said method being characterized in that it employs one of the proteins of claims 3, 5, 8, or 11.
25. A Semaphorin Z inhibitor obtained by the screening method of claim 24.
- 50 26. A Semaphorin Z inhibitor of claim 25 which comprises the protein of claim 13, the polypeptide of claim 19 or 20, or the antibody of claim 23.
27. A CNS-neuron regeneration promoter which is characterized in that it contains at least one of the DNA or RNA of claim 22, or a chemically modified variant thereof, or the Semaphorin Z inhibitor of claim 25 or 26.
- 55 28. A neurite outgrowth inhibitor for PNS-neuron, characterized in that it contains at least one of the proteins of claims 3, 5, 8, or 11.

29. A transgenic animal which has one of the DNAs of claims 1, 4, 6, 7, 9, 10, or 12 artificially inserted into its chromosome, or which has been knocked out.

5

10

15

20

25

30

35

40

45

50

55

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9





Fig. 10



INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03517

A. CLASSIFICATION OF SUBJECT MATTER Int. C16 C12N15/12, C07K14/47, C12P21/02, C12N1/21, C12N5/10, C12N7/01, C07K16/18, C12P21/08, A61K38/17, A01K1/027// (C12N1/21, C12R1:19), (C12P21/02, C12R1:19), (C12N5/10, C12R1:91)
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Int. C16 C12N15/12, C07K14/47, C12P21/02, C12N1/21, C12N5/10, C12N7/01, C07K16/18, C12P21/08, A61K38/17, A01K1/027

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched.

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, BIOSIS PREVIEWS, WPI, WPI/L, GENETYX-CD

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Science, Vol. 259, 1993, Christine E. Bandtlow, et al., "Role of Intracellular Calcium in NI-35-Evoked Collapse of Neuronal Growth Cones", see p. 80-83	1 - 29
A	Cell, Vol. 75, Dec. 31, 1993, Alex L. Kolodkin, et al., "The semaphorin Genes Encode a Family of Transmembrane and Secreted Growth Cone Guidance Molecules", see p. 1389-1399	1 - 29
A	Cell, Vol. 81, May 19, 1995, Alex L. Kolodkin, et al., "Semaphorin II Can Function as a Selective Inhibitor of Specific Synaptic Arborizations", see p. 631-639	1 - 29
A	Nature Genet., Vol. 10, 1995, R. Berry, et al., "Gene-based sequence-tagged-sites (STSs) as the basis for a human gene map", see p. 415-423	14-17, 21
A	Nature Genet., Vol. 4, 1993, M.D. Adams, et al., "Rapid cDNA sequencing (expressed sequence tags)	14-17, 21

☒ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "Z" document member of the same patent family

Date of the actual completion of the international search
February 25, 1997 (25. 02. 97)

Date of mailing of the international search report
March 25, 1997 (25. 03. 97)

Name and mailing address of the ISA/
Japanese Patent Office

Authorized officer

Facsimile No.

Telephone No.

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/JP96/03517

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	from a directionally cloned human infant brain cDNA library", see p. 373-380	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

